Ten-Eleven Translocation Family Proteins: Structure, Biological Functions, Diseases, and Targeted Therapy

Abstract

Ten-eleven translocation (TET) family proteins are Fe(II)- and α-ketoglutarate-dependent dioxygenases, comprising three family members: TET1, TET2, and TET3. These enzymes drive DNA demethylation by sequentially oxidizing 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine. Through these reactions, TET proteins remodel the epigenetic landscape and interact with transcription factors and RNA polymerase II to regulate gene expression, cell lineage specification, and embryonic development. Mutations and dysregulation of TETs have been associated with the pathogenesis of various diseases, including the nervous system, immune system, and metabolic diseases, as well as cancers. Therapeutic modulation of TETs may be an effective strategy for the treatment of these diseases. Here, we provide a comprehensive overview of the mechanisms by which TET proteins mediate DNA demethylation and detail their biological functions. Additionally, we highlight recent advances in understanding the molecular mechanisms linking TET dysregulation to disease pathogenesis and explore their potential as therapeutic targets. This review supplements the current understanding of the critical role of epigenetic regulation in disease pathogenesis and further facilitates the rational design of targeted therapeutic agents for diseases associated with mutations and dysregulation of TETs.

Keywords

Biological functions / Demethylation / Diseases / Ten-eleven translocation / Therapeutic strategies

References

[1] C. H. Waddington, “The epigenotype. 1942,” International Journal of Epidemiology 41 (2012): 10-13.

[2] Y.-L. Wu, Z.-J. Lin, C.-C. Li, et al., “Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study,” Signal Transduction and Targeted Therapy 8 (2023): 98.

[3] S. Ito, A. C. D'alessio, O. V. Taranova, K. Hong, L. C. Sowers, and Y. Zhang, “Role of Tet Proteins in 5mC to 5hmC Conversion, ES-cell Self-renewal and Inner Cell Mass Specification,” Nature 466 (2010): 1129-1133.

[4] A. Parry, S. Rulands, and W. Reik, “Active Turnover of DNA Methylation During Cell Fate Decisions,” Nature Reviews Genetics 22 (2021): 59-66.

[5] T. Fu, L. Liu, Q.-L. Yang, et al., “Thymine DNA Glycosylase Recognizes the Geometry Alteration of minor Grooves Induced by 5-formylcytosine and 5-carboxylcytosine,” Chemical Science 10 (2019): 7407-7417.

[6] M. Tahiliani, K. P. Koh, Y. Shen, et al., “Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1,” Science 324 (2009): 930-935.

[7] S. Ito, L. Shen, Q. Dai, et al., “Tet Proteins Can Convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine,” Science 333 (2011): 1300-1303.

[8] S. Kriaucionis and N. Heintz, “The Nuclear DNA Base 5-hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain,” Science 324 (2009): 929-930.

[9] M. Zhang, J. Wang, K. Zhang, et al., “Ten-eleven Translocation 1 Mediated-DNA Hydroxymethylation Is Required for Myelination and Remyelination in the Mouse Brain,” Nature Communications 12 (2021): 5091.

[10] B. Liu, D. Xie, X. Huang, et al., “Skeletal Muscle TET3 Promotes Insulin Resistance Through Destabilisation of PGC-1α,” Diabetologia 67 (2024): 724-737.

[11] I. F. López-Moyado, M. Ko, P. G. Hogan, and A. Rao, “TET Enzymes in the Immune System: From DNA Demethylation to Immunotherapy, Inflammation, and Cancer,” Annual Review of Immunology 42 (2024): 455-488.

[12] R. Ono, T. Taki, T. Taketani, M. Taniwaki, H. Kobayashi, and Y. Hayashi, “LCX, Leukemia-associated Protein With a CXXC Domain, Is Fused to MLL in Acute Myeloid Leukemia With Trilineage Dysplasia Having T(10;11)(q22;q23),” Cancer Research 62 (2002): 4075-4080.

[13] R. B. Lorsbach, J. Moore, S. Mathew, S. C. Raimondi, S. T. Mukatira, and J. R. Downing, “TET1, a Member of a Novel Protein family, Is Fused to MLL in Acute Myeloid Leukemia Containing the T(10;11)(q22;q23),” Leukemia 17 (2003): 637-641.

[14] C. Dong, H. Zhang, C. Xu, C. H. Arrowsmith, and J. Min, “Structure and Function of Dioxygenases in Histone Demethylation and DNA/RNA Demethylation,” IUCrJ 1 (2014): 540-549.

[15] A. M. Jankowska, H. Szpurka, R. V. Tiu, et al., “Loss of Heterozygosity 4q24 and TET2 Mutations Associated With Myelodysplastic/Myeloproliferative Neoplasms,” Blood 113 (2009): 6403-6410.

[16] K. D. Rasmussen and K. Helin, “Role of TET Enzymes in DNA Methylation, Development, and Cancer,” Genes & development 30 (2016): 733-750.

[17] X. Wu and Y. Zhang, “TET-mediated Active DNA Demethylation: Mechanism, Function and Beyond,” Nature Reviews Genetics 18 (2017): 517-534.

[18] M. Ko, J. An, H. S. Bandukwala, et al., “Modulation of TET2 Expression and 5-methylcytosine Oxidation by the CXXC Domain Protein IDAX,” Nature 497 (2013): 122-126.

[19] W. A. Pastor, L. Aravind, and A. Rao, “TETonic Shift: Biological Roles of TET Proteins in DNA Demethylation and Transcription,” Nature Reviews Molecular Cell Biology 14 (2013): 341-356.

[20] L. Hu, Z. Li, J. Cheng, et al., “Crystal Structure of TET2-DNA Complex: Insight Into TET-mediated 5mC Oxidation,” Cell 155 (2013): 1545-1555.

[21] X.-J. Zhang, B.-B. Han, Z.-Y. Shao, et al., “Auto-suppression of Tet Dioxygenases Protects the Mouse Oocyte Genome From Oxidative Demethylation,” Nature structural & molecular biology 31 (2024): 42-53.

[22] L. Guo, T. Hong, Y.-T. Lee, et al., “Perturbing TET2 Condensation Promotes Aberrant Genome-wide DNA Methylation and Curtails Leukaemia Cell Growth,” Nature Cell Biology 26 (2024): 2154-2167.

[23] D. S. Dunican, S. Pennings, and R. R. Meehan, “The CXXC-TET Bridge-mind the Methylation Gap!,” Cell Research 23 (2013): 973-974.

[24] A. Onodera, M. Kiuchi, K. Kokubo, and T. Nakayama, “Epigenetic Regulation of Inflammation by CxxC Domain-containing Proteins,” Immunological Reviews 305 (2022): 137-151.

[25] J. Yang, N. Bashkenova, R. Zang, X. Huang, and J. Wang, “The Roles of TET family Proteins in Development and Stem Cells,” Development (Cambridge, England) 147 (2020), https://doi.org/10.1242/dev.183129.

[26] H. Wu and Y. Zhang, “Reversing DNA Methylation: Mechanisms, Genomics, and Biological Functions,” Cell 156 (2014): 45-68.

[27] L. Ren, C. Gao, Z. Duren, and Y. Wang, “GuidingNet: Revealing Transcriptional Cofactor and Predicting Binding for DNA Methyltransferase by Network Regularization,” Briefings in Bioinformatics 22 (2021), https://doi.org/10.1093/bib/bbaa245.

[28] J. Barau, A. Teissandier, N. Zamudio, et al., “The DNA Methyltransferase DNMT3C Protects Male Germ Cells From Transposon Activity,” Science 354 (2016): 909-912.

[29] R. L. Tiedemann, J. Hrit, Q. Du, et al., “UHRF1 ubiquitin Ligase Activity Supports the Maintenance of Low-density CpG Methylation,” Nucleic Acids Res. 52 (2024): 13733-13756.

[30] F. Lyko, “The DNA Methyltransferase family: A Versatile Toolkit for Epigenetic Regulation,” Nature Reviews Genetics 19 (2018): 81-92.

[31] C.-X. Song, K. E. Szulwach, Q. Dai, et al., “Genome-wide Profiling of 5-formylcytosine Reveals Its Roles in Epigenetic Priming,” Cell 153 (2013): 678-691.

[32] R. M. Kohli and Y. Zhang, “TET Enzymes, TDG and the Dynamics of DNA Demethylation,” Nature 502 (2013): 472-479.

[33] L. S. Pidugu, Q. Dai, S. S. Malik, E. Pozharski, and A. C. Drohat, “Excision of 5-Carboxylcytosine by Thymine DNA Glycosylase,” Journal of the American Chemical Society 141 (2019): 18851-18861.

[34] C. T. Coey, S. S. Malik, L. S. Pidugu, K. M. Varney, E. Pozharski, and A. C. Drohat, “Structural Basis of Damage Recognition by Thymine DNA Glycosylase: Key Roles for N-terminal Residues,” Nucleic Acids Res. 44 (2016): 10248-10258.

[35] A. R. Weber, C. Krawczyk, A. B. Robertson, et al., “Biochemical Reconstitution of TET1-TDG-BER-dependent Active DNA Demethylation Reveals a Highly Coordinated Mechanism,” Nature Communications 7 (2016): 10806.

[36] M. Guo, Y. Peng, A. Gao, C. Du, and J. G. Herman, “Epigenetic Heterogeneity in Cancer,” Biomarker Research 7 (2019): 23.

[37] S. Schiesser, B. Hackner, T. Pfaffeneder, et al., “Mechanism and Stem-cell Activity of 5-carboxycytosine Decarboxylation Determined by Isotope Tracing,” Angewandte Chemie (International ed in English) 51 (2012): 6516-6520.

[38] Z. Liutkevičiu̅Tė, E. Kriukienė, J. Ličytė, M. Rudytė, G. Urbanavičiu̅Tė, and S. Klimašauskas, “Direct Decarboxylation of 5-carboxylcytosine by DNA C5-methyltransferases,” Journal of the American Chemical Society 136 (2014): 5884-5887.

[39] J. E. Duan, Z. C. Jiang, F. Alqahtani, et al., “Methylome Dynamics of Bovine Gametes and in Vivo Early Embryos,” Frontiers in Genetics 10 (2019): 512.

[40] M. V. C. Greenberg and D. Bourc'his, “The Diverse Roles of DNA Methylation in Mammalian Development and Disease,” Nature Reviews Molecular Cell Biology 20 (2019): 590-607.

[41] F. Miura, Y. Enomoto, R. Dairiki, and T. Ito, “Amplification-free Whole-Genome Bisulfite Sequencing by Post-bisulfite Adaptor Tagging,” Nucleic Acids Res. 40 (2012): e136.

[42] H. J. Lee, T. A. Hore, and W. Reik, “Reprogramming the Methylome: Erasing Memory and Creating Diversity,” Cell Stem Cell 14 (2014): 710-719.

[43] C. Luo, P. Hajkova, and J. R. Ecker, “Dynamic DNA Methylation: In the Right Place at the Right Time,” Science 361 (2018): 1336-1340.

[44] S. Seisenberger, J. R. Peat, T. A. Hore, F. Santos, W. Dean, and W. Reik, “Reprogramming DNA Methylation in the Mammalian Life Cycle: Building and Breaking Epigenetic Barriers,” Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 368 (2013): 20110330.

[45] Y. Zeng and T. Chen, “DNA Methylation Reprogramming During Mammalian Development,” Genes (Basel) 10 (2019): 257.

[46] Z. D. Smith, M. M. Chan, T. S. Mikkelsen, et al., “A Unique Regulatory Phase of DNA Methylation in the Early Mammalian Embryo,” Nature 484 (2012): 339-344.

[47] K. Iqbal, S. G. Jin, G. P. Pfeifer, and P. E. Szabó, “Reprogramming of the Paternal Genome Upon Fertilization Involves Genome-wide Oxidation of 5-methylcytosine,” Pnas 108 (2011): 3642-3647.

[48] R. Xu, C. Li, X. Liu, and S. Gao, “Insights Into Epigenetic Patterns in Mammalian Early Embryos,” Protein Cell 12 (2021): 7-28.

[49] M. Wossidlo, T. Nakamura, K. Lepikhov, et al., “5-Hydroxymethylcytosine in the Mammalian Zygote Is Linked With Epigenetic Reprogramming,” Nature Communications 2 (2011): 241.

[50] T.-P. Gu, F. Guo, H. Yang, et al., “The Role of Tet3 DNA Dioxygenase in Epigenetic Reprogramming by Oocytes,” Nature 477 (2011): 606-610.

[51] A. Inoue, L. Shen, Q. Dai, C. He, and Y. Zhang, “Generation and Replication-dependent Dilution of 5fC and 5caC During Mouse Preimplantation Development,” Cell Research 21 (2011): 1670-1676.

[52] A. Inoue, S. Matoba, and Y. Zhang, “Transcriptional Activation of Transposable Elements in Mouse Zygotes Is Independent of Tet3-mediated 5-methylcytosine Oxidation,” Cell Research 22 (2012): 1640-1649.

[53] W. Reik, W. Dean, and J. Walter, “Epigenetic Reprogramming in Mammalian Development,” Science 293 (2001): 1089-1093.

[54] R. Amouroux, B. Nashun, K. Shirane, et al., “De Novo DNA Methylation Drives 5hmC Accumulation in Mouse Zygotes,” Nature Cell Biology 18 (2016): 225-233.

[55] L. Shen, A. Inoue, J. He, et al., “Tet3 and DNA Replication Mediate Demethylation of both the Maternal and Paternal Genomes in Mouse Zygotes,” Cell Stem Cell 15 (2014): 459-471.

[56] Z. Chen and Y. Zhang, “Role of Mammalian DNA Methyltransferases in Development,” Annual Review of Biochemistry 89 (2020): 135-158.

[57] J. Salvaing, T. Aguirre-Lavin, C. Boulesteix, G. Lehmann, P. Debey, and N. Beaujean, “5-Methylcytosine and 5-hydroxymethylcytosine Spatiotemporal Profiles in the Mouse Zygote,” PLoS ONE 7 (2012): e38156.

[58] T. Nakamura, Y. Arai, H. Umehara, et al., “PGC7/Stella Protects Against DNA Demethylation in Early Embryogenesis,” Nature Cell Biology 9 (2007): 64-71.

[59] Y. Li, Z. Zhang, J. Chen, et al., “Stella Safeguards the Oocyte Methylome by Preventing De Novo Methylation Mediated by DNMT1,” Nature 564 (2018): 136-140.

[60] T. Nakamura, Y. Liu, H. Nakashima, et al., “PGC7 binds Histone H3K9me2 to Protect Against Conversion of 5mC to 5hmC in Early Embryos,” Nature 486 (2012): 415-419.

[61] S. Kagiwada, K. Kurimoto, T. Hirota, M. Yamaji, and M. Saitou, “Replication-coupled Passive DNA Demethylation for the Erasure of Genome Imprints in Mice,” Embo Journal 32 (2013): 340-353.

[62] S. Yamaguchi, K. Hong, R. Liu, et al., “Dynamics of 5-methylcytosine and 5-hydroxymethylcytosine During Germ Cell Reprogramming,” Cell Research 23 (2013): 329-339.

[63] S. Yamaguchi, L. Shen, Y. Liu, D. Sendler, and Y. Zhang, “Role of Tet1 in Erasure of Genomic Imprinting,” Nature 504 (2013): 460-464.

[64] S. Seisenberger, S. Andrews, F. Krueger, et al., “The Dynamics of Genome-wide DNA Methylation Reprogramming in Mouse Primordial Germ Cells,” Molecular Cell 48 (2012): 849-862.

[65] J. Hargan-Calvopina, S. Taylor, H. Cook, et al., “Stage-Specific Demethylation in Primordial Germ Cells Safeguards Against Precocious Differentiation,” Developmental Cell 39 (2016): 75-86.

[66] M. Dawlaty, A. Breiling, T. Le, et al., “Combined Deficiency of Tet1 and Tet2 Causes Epigenetic Abnormalities but Is Compatible With Postnatal Development,” Developmental Cell 24 (2013): 310-323.

[67] K. P. Koh, A. Yabuuchi, S. Rao, et al., “Tet1 and Tet2 Regulate 5-hydroxymethylcytosine Production and Cell Lineage Specification in Mouse Embryonic Stem Cells,” Cell Stem Cell 8 (2011): 200-213.

[68] S. E. Ross and O. Bogdanovic, “TET Enzymes, DNA Demethylation and Pluripotency,” Biochemical Society Transactions 47 (2019): 875-885.

[69] J. C. Sabino, M. R. de Almeida, P. L. Abreu, et al., “Epigenetic Reprogramming by TET Enzymes Impacts co-transcriptional R-loops,” Elife 11 (2022): e69476.

[70] M. Dawlaty, A. Breiling, T. Le, et al., “Loss of Tet Enzymes Compromises Proper Differentiation of Embryonic Stem Cells,” Developmental Cell 29 (2014): 102-111.

[71] I. Beerman and D. J. Rossi, “Epigenetic Control of Stem Cell Potential During Homeostasis, Aging, and Disease,” Cell Stem Cell 16 (2015): 613-625.

[72] K. Joshi, S. Liu, P. Breslin SJ, and J. Zhang, “Mechanisms That Regulate the Activities of TET Proteins,” Cellular and Molecular Life Sciences 79 (2022): 363.

[73] S. Chrysanthou, Q. Tang, J. Lee, et al., “The DNA Dioxygenase Tet1 Regulates H3K27 Modification and Embryonic Stem Cell Biology Independent of Its Catalytic Activity,” Nucleic Acids Res. 50 (2022): 3169-3189.

[74] S. Yamaguchi, K. Hong, R. Liu, et al., “Tet1 controls Meiosis by Regulating Meiotic Gene Expression,” Nature 492 (2012): 443-447.

[75] M. Dawlaty, K. Ganz, B. Powell, et al., “Tet1 is Dispensable for Maintaining Pluripotency and Its Loss is Compatible With Embryonic and Postnatal Development,” Cell Stem Cell 9 (2011): 166-175.

[76] Z. Li, X. Cai, C. Cai, et al., “Deletion of Tet2 in Mice Leads to Dysregulated Hematopoietic Stem Cells and Subsequent Development of Myeloid Malignancies,” Blood 118 (2011): 4509-4518.

[77] K. Ito, J. Lee, S. Chrysanthou, et al., “Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis,” Cell reports 28 (2019): 2480-2490.e2484.

[78] H. Dai, B. Wang, L. Yang, et al., “TET-mediated DNA Demethylation Controls Gastrulation by Regulating Lefty-Nodal Signalling,” Nature 538 (2016): 528-532.

[79] S. Cheng, M. Mittnenzweig, Y. Mayshar, et al., “The Intrinsic and Extrinsic Effects of TET Proteins During Gastrulation,” Cell 185 (2022): 3169-3185.e3120.

[80] X. Li, X. Yue, W. A. Pastor, et al., “Tet Proteins Influence the Balance Between Neuroectodermal and Mesodermal Fate Choice by Inhibiting Wnt Signaling,” Pnas 113 (2016): E8267-e8276.

[81] G. Hon, C. Song, T. Du, et al., “5mC oxidation by Tet2 Modulates Enhancer Activity and Timing of Transcriptome Reprogramming During Differentiation,” Molecular Cell 56 (2014): 286-297.

[82] J. Lan, N. Rajan, M. Bizet, et al., “Functional Role of Tet-mediated RNA Hydroxymethylcytosine in Mouse ES Cells and During Differentiation,” Nature Communications 11 (2020): 4956.

[83] J. Yang, R. Guo, H. Wang, et al., “Tet Enzymes Regulate Telomere Maintenance and Chromosomal Stability of Mouse ESCs,” Cell reports 15 (2016): 1809-1821.

[84] N. Verma, H. Pan, L. C. Doré, et al., “TET Proteins Safeguard Bivalent Promoters From De Novo Methylation in human Embryonic Stem Cells,” Nature Genetics 50 (2018): 83-95.

[85] T. Langlois, B. da Costa Reis Monte-Mor, G. Lenglet, et al., “TET2 deficiency Inhibits Mesoderm and Hematopoietic Differentiation in human Embryonic Stem Cells,” Stem Cells 32 (2014): 2084-2097.

[86] Y. H. Hur, S. Feng, K. F. Wilson, R. A. Cerione, and M. A. Antonyak, “Embryonic Stem Cell-Derived Extracellular Vesicles Maintain ESC Stemness by Activating FAK,” Developmental Cell 56 (2021): 277-291.e276.

[87] M. M. A. Mamun, M. R. Khan, Y. Zhu, et al., “Stub1 maintains Proteostasis of Master Transcription Factors in Embryonic Stem Cells,” Cell reports 39 (2022): 110919.

[88] R. A. Young, “Control of the Embryonic Stem Cell state,” Cell 144 (2011): 940-954.

[89] Y. Wu, Z. Guo, Y. Liu, et al., “Oct4 and the Small Molecule Inhibitor, SC1, Regulates Tet2 Expression in Mouse Embryonic Stem Cells,” Molecular Biology Reports 40 (2013): 2897-2906.

[90] W. Zhang, W. Xia, Q. Wang, et al., “Isoform Switch of TET1 Regulates DNA Demethylation and Mouse Development,” Molecular Cell 64 (2016): 1062-1073.

[91] L. Liu, “Linking Telomere Regulation to Stem Cell Pluripotency,” Trends in Genetics 33 (2017): 16-33.

[92] J. Huang, F. Wang, M. Okuka, et al., “Association of Telomere Length With Authentic Pluripotency of ES/iPS Cells,” Cell Research 21 (2011): 779-792.

[93] X. Zhang, Y. Zhang, C. Wang, and X. Wang, “TET (Ten-eleven translocation) family Proteins: Structure, Biological Functions and Applications,” Signal Transduction and Targeted Therapy 8 (2023): 297.

[94] A. Paniri, M. M. Hosseini, and H. Akhavan-Niaki, “Alzheimer's Disease-Related Epigenetic Changes: Novel Therapeutic Targets,” Molecular Neurobiology 61, no. 3 (2023): 1282-1317.

[95] M. J. Armstrong, Y. Jin, S. M. Vattathil, et al., “Role of TET1-mediated Epigenetic Modulation in Alzheimer's Disease,” Neurobiology of Disease 185 (2023): 106257.

[96] I. S. Fetahu, D. Ma, K. Rabidou, et al., “Epigenetic Signatures of Methylated DNA Cytosine in Alzheimer's Disease,” Science Advances 5 (2019): eaaw2880.

[97] Y. Zhang, Z. Zhang, L. Li, et al., “Selective Loss of 5hmC Promotes Neurodegeneration in the Mouse Model of Alzheimer's Disease,” Faseb Journal 34 (2020): 16364-16382.

[98] J. N. Kuehner, J. Chen, E. C. Bruggeman, et al., “5-hydroxymethylcytosine Is Dynamically Regulated During Forebrain Organoid Development and Aberrantly Altered in Alzheimer's Disease,” Cell reports 35 (2021): 109042.

[99] A. van Hummel, G. Taleski, J. Sontag, et al., “Methyl Donor Supplementation Reduces Phospho-Tau, Fyn and Demethylated Protein Phosphatase 2A Levels and Mitigates Learning and Motor Deficits in a Mouse Model of Tauopathy,” Neuropathology and Applied Neurobiology 49 (2023): e12931.

[100] J. N. Cochran, E. G. Geier, L. W. Bonham, et al., “Non-coding and Loss-of-Function Coding Variants in TET2 Are Associated With Multiple Neurodegenerative Diseases,” American Journal of Human Genetics 106 (2020): 632-645.

[101] G. Gontier, M. Iyer, J. M. Shea, et al., “Tet2 Rescues Age-Related Regenerative Decline and Enhances Cognitive Function in the Adult Mouse Brain,” Cell reports 22 (2018): 1974-1981.

[102] X. Kong, Z. Gong, L. Zhang, et al., “JAK2/STAT3 signaling Mediates IL-6-inhibited Neurogenesis of Neural Stem Cells Through DNA Demethylation/Methylation,” Brain, Behavior, and Immunity 79 (2019): 159-173.

[103] S. P. Pradhan, P. Tejaswani, A. Behera, and P. K. Sahu, “Phytomolecules From Conventional to Nano Form: Next-generation Approach for Parkinson's Disease,” Ageing Research Reviews 93 (2024): 102136.

[104] V. Yazar, V. L. Dawson, T. M. Dawson, and S. U. Kang, “DNA Methylation Signature of Aging: Potential Impact on the Pathogenesis of Parkinson's Disease,” Journal of Parkinson's Disease 13 (2023): 145-164.

[105] J. J. Gaare, K. Brügger, G. S. Nido, and C. Tzoulis, “DNA Methylation Age Acceleration Is Not Associated With Age of Onset in Parkinson's Disease,” Movement Disorders 38 (2023): 2064-2071.

[106] L. L. Marshall, B. A. Killinger, E. Ensink, et al., “Epigenomic Analysis of Parkinson's disease Neurons Identifies Tet2 Loss as Neuroprotective,” Nature Neuroscience 23 (2020): 1203-1214.

[107] T. Wu, T. Liu, X. Li, et al., “TET2-mediated Cdkn2A DNA Hydroxymethylation in Midbrain Dopaminergic Neuron Injury of Parkinson's Disease,” Human Molecular Genetics 29 (2020): 1239-1252.

[108] Z. Zhu, Y. Li, J. Xu, et al., “CDKL5 deficiency in Adult Glutamatergic Neurons Alters Synaptic Activity and Causes Spontaneous Seizures via TrkB Signaling,” Cell reports 42 (2023): 113202.

[109] N. Çarçak, F. Onat, and E. Sitnikova, “Astrocytes as a Target for Therapeutic Strategies in Epilepsy: Current Insights,” Frontiers in Molecular Neuroscience 16 (2023): 1183775.

[110] D. Pensold, J. Reichard, K. M. J. Van Loo, et al., “DNA Methylation-Mediated Modulation of Endocytosis as Potential Mechanism for Synaptic Function Regulation in Murine Inhibitory Cortical Interneurons,” Cerebral Cortex 30 (2020): 3921-3937.

[111] L. de Nijs, K. Choe, H. Steinbusch, et al., “DNA Methyltransferase Isoforms Expression in the Temporal Lobe of Epilepsy Patients With a History of Febrile Seizures,” Clin Epigenetics 11 (2019): 118.

[112] F. Kong, L. Lang, J. Hu, X. Zhang, M. Zhong, and C. Ma, “A Novel Epigenetic Marker, Ten-eleven Translocation family Member 2 (TET2), Is Identified in the Intractable Epileptic Brain and Regulates ATP Binding Cassette Subfamily B Member 1 (ABCB1) in the Blood-brain Barrier,” Bioengineered 13 (2022): 6638-6649.

[113] X. Xiao, X. Wu, P. Yang, et al., “Status Epilepticus Induced Gadd45b Is Required for Augmented Dentate Neurogenesis,” Stem Cell Res 49 (2020): 102102.

[114] K. Zybura-Broda, R. Amborska, M. Ambrozek-Latecka, et al., “Epigenetics of Epileptogenesis-Evoked Upregulation of Matrix Metalloproteinase-9 in Hippocampus,” PLoS ONE 11 (2016): e0159745.

[115] R. Ryley Parrish, A. Albertson, S. Buckingham, et al., “Status Epilepticus Triggers Early and Late Alterations in Brain-derived Neurotrophic Factor and NMDA Glutamate Receptor Grin2b DNA Methylation Levels in the Hippocampus,” Neuroscience 248 (2013): 602-619.

[116] M. Iqbal, X. Xiao, S. Zafar, et al., “Forced Physical Training Increases Neuronal Proliferation and Maturation With Their Integration Into Normal Circuits in Pilocarpine Induced Status Epilepticus Mice,” Neurochemical Research 44 (2019): 2590-2605.

[117] S. Wahane, D. Halawani, X. Zhou, and H. Zou, “Epigenetic Regulation of Axon Regeneration and Glial Activation in Injury Responses,” Frontiers in Genetics 10 (2019): 640.

[118] Y. Wang, J. Wang, H. Wang, et al., “Tet1 Overexpression and Decreased DNA Hydroxymethylation Protect Neurons against Cell Death after Injury by Increasing Expression of Genes Involved in Cell Survival,” World neurosurgery 126 (2019): e713-e722.

[119] J. Y. Hong, G. Davaa, H. Yoo, K. Hong, and J. K. Hyun, “Ascorbic Acid Promotes Functional Restoration After Spinal Cord Injury Partly by Epigenetic Modulation,” Cells 9 (2020): 1310.

[120] G. Davaa, J. Y. Hong, T. U. Kim, et al., “Exercise Ameliorates Spinal Cord Injury by Changing DNA Methylation,” Cells 10 (2021): 143.

[121] M. A. Petrie, A. Sharma, E. B. Taylor, M. Suneja, and R. K. Shields, “Impact of Short- and Long-term Electrically Induced Muscle Exercise on Gene Signaling Pathways, Gene Expression, and PGC1a Methylation in Men With Spinal Cord Injury,” Physiological Genomics 52 (2020): 71-80.

[122] M. A. Petrie, E. B. Taylor, M. Suneja, and R. K. Shields, “Genomic and Epigenomic Evaluation of Electrically Induced Exercise in People with Spinal Cord Injury: Application to Precision Rehabilitation,” Physical Therapy 102 (2022): pzab243.

[123] Y. E. Loh, A. Koemeter-Cox, M. J. Finelli, L. Shen, R. H. Friedel, and H. Zou, “Comprehensive Mapping of 5-hydroxymethylcytosine Epigenetic Dynamics in Axon Regeneration,” Epigenetics 12 (2017): 77-92.

[124] B. Jiang, W. Zhang, T. Yang, et al., “Demethylation of G-Protein-Coupled Receptor 151 Promoter Facilitates the Binding of Krüppel-Like Factor 5 and Enhances Neuropathic Pain After Nerve Injury in Mice,” Journal of Neuroscience 38 (2018): 10535-10551.

[125] B. C. Jiang, L. N. He, X. B. Wu, et al., “Promoted Interaction of C/EBPα With Demethylated Cxcr3 Gene Promoter Contributes to Neuropathic Pain in Mice,” Journal of Neuroscience 37 (2017): 685-700.

[126] H. Sun, Z. Miao, H. Wang, et al., “DNA Hydroxymethylation Mediated Traumatic Spinal Injury by Influencing Cell Death-related Gene Expression,” Journal of Cellular Biochemistry 119 (2018): 9295-9302.

[127] F. Ji, C. Zhao, B. Wang, Y. Tang, Z. Miao, and Y. Wang, “The Role of 5-hydroxymethylcytosine in Mitochondria After Ischemic Stroke,” Journal of Neuroscience Research 96 (2018): 1717-1726.

[128] C. M. Phillips, S. M. Stamatovic, R. F. Keep, and A. V. Andjelkovic, “Epigenetics and Stroke: Role of DNA Methylation and Effect of Aging on Blood-brain Barrier Recovery,” Fluids Barriers CNS 20 (2023): 14.

[129] K. C. Morris-Blanco, A. K. Chokkalla, M. J. Bertogliat, and R. Vemuganti, “TET3 regulates DNA Hydroxymethylation of Neuroprotective Genes Following Focal Ischemia,” Journal of Cerebral Blood Flow and Metabolism 41 (2021): 590-603.

[130] Z. Miao, Y. He, N. Xin, et al., “Altering 5-hydroxymethylcytosine Modification Impacts Ischemic Brain Injury,” Human Molecular Genetics 24 (2015): 5855-5866.

[131] Y. Tang, S. Han, T. Asakawa, et al., “Effects of Intracerebral Hemorrhage on 5-hydroxymethylcytosine Modification in Mouse Brains,” Neuropsychiatr Dis Treat 12 (2016): 617-624.

[132] K. C. Morris-Blanco, T. Kim, M. S. Lopez, M. J. Bertogliat, B. Chelluboina, and R. Vemuganti, “Induction of DNA Hydroxymethylation Protects the Brain after Stroke,” Stroke; A Journal of Cerebral Circulation 50 (2019): 2513-2521.

[133] Q. Ma, C. Dasgupta, G. Shen, Y. Li, and L. Zhang, “MicroRNA-210 Downregulates TET2 and Contributes to Inflammatory Response in Neonatal Hypoxic-ischemic Brain Injury,” Journal of neuroinflammation 18 (2021): 6.

[134] J. Li, L. Li, X. Sun, et al., “Role of Tet2 in Regulating Adaptive and Innate Immunity,” Frontiers in Cell and Developmental Biology 9 (2021): 665897.

[135] B. Cong, Q. Zhang, and X. Cao, “The Function and Regulation of TET2 in Innate Immunity and Inflammation,” Protein Cell 12 (2021): 165-173.

[136] S. Tanaka, W. Ise, T. Inoue, et al., “Tet2 and Tet3 in B Cells Are Required to Repress CD86 and Prevent Autoimmunity,” Nature Immunology 21 (2020): 950-961.

[137] A. Teghanemt, K. Misel-Wuchter, J. Heath, et al., “DNA Demethylation Fine-tunes IL-2 Production During Thymic Regulatory T Cell Differentiation,” Embo Reports 24 (2023): e55543.

[138] R. Vento-Tormo, D. Álvarez-Errico, A. Garcia-Gomez, et al., “DNA Demethylation of Inflammasome-associated Genes Is Enhanced in Patients With Cryopyrin-associated Periodic Syndromes,” Journal of Allergy and Clinical Immunology 139 (2017): 202-211.e206.

[139] W. Zhang, Z. Chen, K. Yi, et al., “TET2-mediated Upregulation of 5-hydroxymethylcytosine in LRRC39 Promoter Promotes Th1 Response in Association With Downregulated Treg Response in Vogt-Koyanagi-Harada Disease,” Clinical Immunology 250 (2023): 109323.

[140] S. P. Pandey, M. J. Bender, A. C. McPherson, et al., “Tet2 deficiency Drives Liver Microbiome Dysbiosis Triggering Tc1 Cell Autoimmune hepatitis,” Cell Host & Microbe 30 (2022): 1003-1019.e1010.

[141] A. S. Arterbery, A. Osafo-Addo, Y. Avitzur, et al., “Production of Proinflammatory Cytokines by Monocytes in Liver-Transplanted Recipients With De Novo Autoimmune Hepatitis Is Enhanced and Induces TH1-Like Regulatory T Cells,” Journal of Immunology 196 (2016): 4040-4051.

[142] M. Peiseler, M. Sebode, B. Franke, et al., “FOXP3+ regulatory T Cells in Autoimmune hepatitis Are Fully Functional and Not Reduced in Frequency,” Journal of Hepatology 57 (2012): 125-132.

[143] A. Kawabe, K. Yamagata, S. Kato, et al., “Role of DNA Dioxygenase Ten-Eleven Translocation 3 (TET3) in Rheumatoid Arthritis Progression,” Arthritis Research & Therapy 24 (2022): 222.

[144] Z. Zhao, Z. Zhang, J. Li, et al., “Sustained TNF-α Stimulation Leads to Transcriptional Memory That Greatly Enhances Signal Sensitivity and Robustness,” Elife 9 (2020), https://doi.org/10.7554/eLife.61965.

[145] O. Morante-Palacios, L. Ciudad, R. Micheroli, et al., “Coordinated Glucocorticoid Receptor and MAFB Action Induces Tolerogenesis and Epigenome Remodeling in Dendritic Cells,” Nucleic Acids Res. 50 (2022): 108-126.

[146] Y. Tang, M. Luo, K. Pan, et al., “DNA Hydroxymethylation Changes in Response to Spinal Cord Damage in a multiple Sclerosis Mouse Model,” Epigenomics 11 (2019): 323-335.

[147] C. Lagos, P. Carvajal, I. Castro, et al., “Association of High 5-hydroxymethylcytosine Levels With Ten Eleven Translocation 2 Overexpression and Inflammation in Sjögren's syndrome Patients,” Clinical Immunology 196 (2018): 85-96.

[148] O. Konsta, C. Le Dantec, A. Charras, et al., “Defective DNA Methylation in Salivary Gland Epithelial Acini From Patients With Sjögren's Syndrome Is Associated With SSB Gene Expression, Anti-SSB/LA Detection, and Lymphocyte Infiltration,” Journal of Autoimmunity 68 (2016): 30-38.

[149] J. Ye, M. Stefan-Lifshitz, and Y. Tomer, “Genetic and Environmental Factors Regulate the Type 1 Diabetes Gene CTSH via Differential DNA Methylation,” Journal of Biological Chemistry 296 (2021): 100774.

[150] M. Stefan-Lifshitz, E. Karakose, L. Cui, et al., “Epigenetic Modulation of β Cells by Interferon-α Via PNPT1/Mir-26a/TET2 Triggers Autoimmune Diabetes,” JCI Insight 4 (2019), https://doi.org/10.1172/jci.insight.126663.

[151] M. G. Scherm, I. Serr, A. M. Zahm, et al., “miRNA142-3p targets Tet2 and Impairs Treg Differentiation and Stability in Models of Type 1 Diabetes,” Nature Communications 10 (2019): 5697.

[152] Q. Zheng, Y. Xu, Y. Liu, et al., “Induction of Foxp3 Demethylation Increases Regulatory CD4+CD25+ T Cells and Prevents the Occurrence of Diabetes in Mice,” Journal of Molecular Medicine (Berl) 87 (2009): 1191-1205.

[153] J. Rui, S. Deng, A. L. Perdigoto, et al., “Tet2 Controls the Responses of β Cells to Inflammation in Autoimmune Diabetes,” Nature Communications 12 (2021): 5074.

[154] Q. Reuschlé, L. Van Heddegem, V. Bosteels, et al., “Loss of Function of XBP1 Splicing Activity of IRE1α Favors B Cell Tolerance Breakdown,” Journal of Autoimmunity 142 (2023): 103152.

[155] M. Xipell, G. M. Lledó, A. C. Egan, et al., “From Systemic Lupus Erythematosus to Lupus Nephritis: The Evolving Road to Targeted Therapies,” Autoimmunity Reviews 22 (2023): 103404.

[156] F. Li, Z. Liang, H. Zhong, et al., “Group 3 Innate Lymphoid Cells Exacerbate Lupus Nephritis by Promoting B Cell Activation in Kidney Ectopic Lymphoid Structures,” Advanced Science (Weinheim) 10 (2023): e2302804.

[157] L. Zhang, F. Du, Q. Jin, et al., “Identification and Characterization of CD8(+) CD27(+) CXCR3(-) T Cell Dysregulation and Progression-Associated Biomarkers in Systemic Lupus Erythematosus,” Advanced Science (Weinheim) 10 (2023): e2300123.

[158] H. Long, H. Yin, L. Wang, M. E. Gershwin, and Q. Lu, “The Critical Role of Epigenetics in Systemic Lupus Erythematosus and Autoimmunity,” Journal of Autoimmunity 74 (2016): 118-138.

[159] B. Richardson, “Epigenetically Altered T Cells Contribute to Lupus Flares,” Cells 8 (2019), https://doi.org/10.3390/cells8020127.

[160] R. C. Ferreira, H. Z. Simons, W. S. Thompson, et al., “Cells With Treg-specific FOXP3 Demethylation but Low CD25 Are Prevalent in Autoimmunity,” Journal of Autoimmunity 84 (2017): 75-86.

[161] X. Wang, C. Zhang, Z. Wu, Y. Chen, and W. Shi, “CircIBTK Inhibits DNA Demethylation and Activation of AKT Signaling Pathway via miR-29b in Peripheral Blood Mononuclear Cells in Systemic Lupus Erythematosus,” Arthritis Research & Therapy 20 (2018): 118.

[162] S. Luo, R. Wu, Q. Li, and G. Zhang, “Epigenetic Regulation of IFI44L Expression in Monocytes Affects the Functions of Monocyte-Derived Dendritic Cells in Systemic Lupus Erythematosus,” Journal of Immunology Research 2022 (2022): 4053038.

[163] H. Hanaoka, T. Nishimoto, Y. Okazaki, T. Takeuchi, and M. Kuwana, “A Unique thymus-derived Regulatory T Cell Subset Associated With Systemic Lupus Erythematosus,” Arthritis Research & Therapy 22 (2020): 88.

[164] H. Cheng, L. Hung-Ke, M. Sheu, C. Lee, Y. Tsai, and D. Lai, “AHR/TET2/NT5E Axis Downregulation Is Associated With the Risk of Systemic Lupus Erythematosus and Its Progression,” Immunology 168 (2023): 654-670.

[165] M. Yang, D. Long, L. Hu, et al., “AIM2 deficiency in B Cells Ameliorates Systemic Lupus Erythematosus by Regulating Blimp-1-Bcl-6 Axis-mediated B-cell Differentiation,” Signal Transduction and Targeted Therapy 6 (2021): 341.

[166] H. Wu, Y. Deng, D. Long, et al., “The IL-21-TET2-AIM2-c-MAF Pathway Drives the T Follicular Helper Cell Response in Lupus-Like Disease,” Clinical and translational medicine 12 (2022): e781.

[167] W. Sung, Y. Lin, D. Hwang, et al., “Methylation of TET2 Promoter Is Associated With Global Hypomethylation and Hypohydroxymethylation in Peripheral Blood Mononuclear Cells of Systemic Lupus Erythematosus Patients,” Diagnostics (Basel) 12 (2022): 3006.

[168] B. Tao, W. Xiang, X. Li, et al., “Regulation of Toll-Like Receptor-mediated Inflammatory Response by microRNA-152-3p-mediated Demethylation of MyD88 in Systemic Lupus Erythematosus,” Inflammation Research 70 (2021): 285-296.

[169] R. Hisada, N. Yoshida, S. Y. K. Orite, et al., “Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin-2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus,” Arthritis Rheumatol 74 (2022): 1204-1210.

[170] X. Gao, Y. Song, J. Wu, et al., “Iron-dependent Epigenetic Modulation Promotes Pathogenic T Cell Differentiation in Lupus,” Journal of Clinical Investigation 132 (2022): e152345.

[171] A. Cardenas, R. P. Fadadu, and G. H. Koppelman, “Epigenome-wide Association Studies of Allergic Disease and the Environment,” Journal of Allergy and Clinical Immunology 152 (2023): 582-590.

[172] A. Cardenas, R. Fadadu, and S. Bunyavanich, “Climate Change and Epigenetic Biomarkers in Allergic and Airway Diseases,” Journal of Allergy and Clinical Immunology 152 (2023): 1060-1072.

[173] G. W. Canonica, G. Varricchi, G. Paoletti, E. Heffler, and J. C. Virchow, “Advancing Precision Medicine in Asthma: Evolution of Treatment Outcomes,” Journal of Allergy and Clinical Immunology 152 (2023): 835-840.

[174] H. K. Somineni, X. Zhang, J. M. Biagini Myers, et al., “Ten-eleven Translocation 1 (TET1) Methylation Is Associated With Childhood Asthma and Traffic-related Air Pollution,” Journal of Allergy and Clinical Immunology 137 (2016): 797-805.e795.

[175] J. Li, J. Sha, L. Sun, D. Zhu, and C. Meng, “Contribution of Regulatory T Cell Methylation Modifications to the Pathogenesis of Allergic Airway Diseases,” Journal of Immunology Research 2021 (2021): 5590217.

[176] L. Yuan, L. Wang, X. Du, et al., “The DNA Methylation of FOXO3 and TP53 as a Blood Biomarker of Late-onset Asthma,” Journal of translational medicine 18 (2020): 467.

[177] X. Yue, S. Trifari, T. Äijö, et al., “Control of Foxp3 Stability through Modulation of TET Activity,” Journal of Experimental Medicine 213 (2016): 377-397.

[178] B. H. Y. Yeung, J. Huang, S. S. An, J. Solway, W. Mitzner, and W. Tang, “Role of Isocitrate Dehydrogenase 2 on DNA Hydroxymethylation in Human Airway Smooth Muscle Cells,” American Journal of Respiratory Cell and Molecular Biology 63 (2020): 36-45.

[179] C. Meng, L. Gu, Y. Li, et al., “Ten-eleven Translocation 2 Modulates Allergic Inflammation by 5-hydroxymethylcytosine Remodeling of Immunologic Pathways,” Human Molecular Genetics 30 (2021): 1985-1995.

[180] L. Tan, T. Qiu, R. Xiang, et al., “Down-regulation of Tet2 Is Associated with Foxp3 TSDR Hypermethylation in Regulatory T Cell of Allergic Rhinitis,” Life Sciences 241 (2020): 117101.

[181] Y. Zhou, Z. Hu, Q. Sun, and Y. Dong, “5-methyladenosine Regulators Play a Crucial Role in Development of Chronic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis,” Scientific Reports 13 (2023): 5941.

[182] 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care 47, S20-s42, (2024).

[183] A. S. Olsen, M. P. Sarras, A. Leontovich, and R. V. Intine, “Heritable Transmission of Diabetic Metabolic Memory in Zebrafish Correlates with DNA Hypomethylation and Aberrant Gene Expression,” Diabetes 61 (2012): 485-491.

[184] E. Yuan, Y. Yang, L. Cheng, et al., “Hyperglycemia Affects Global 5-methylcytosine and 5-hydroxymethylcytosine in Blood Genomic DNA through Upregulation of SIRT6 and TETs,” Clinical Epigenetics 11 (2019): 63.

[185] L. Da, T. Cao, X. Sun, et al., “Hepatic TET3 Contributes to Type-2 Diabetes by Inducing the HNF4α Fetal Isoform,” Nature Communications 11 (2020): 342.

[186] H. Li, X. Zhang, X. Liang, et al., “HNF4α-TET2-FBP1 axis Contributes to Gluconeogenesis and Type 2 Diabetes,” BioRxiv (2024). 2024.2009. 2029.615677.

[187] V. R. Liyanage, J. S. Jarmasz, N. Murugeshan, M. R. Del Bigio, M. Rastegar, and J. R. Davie, “DNA Modifications: Function and Applications in Normal and Disease States,” Biology (Basel) 3 (2014): 670-723.

[188] M. Kim, “DNA Methylation: A Cause and Consequence of Type 2 Diabetes,” Genomics Inform 17 (2019): e38.

[189] Q. Tian, J. Zhao, Q. Yang, et al., “Dietary Alpha-ketoglutarate Promotes Beige Adipogenesis and Prevents Obesity in Middle-aged Mice,” Aging Cell 19 (2020): e13059.

[190] S. Byun, C. H. Lee, H. Jeong, et al., “Loss of Adipose TET Proteins Enhances β-adrenergic Responses and Protects against Obesity by Epigenetic Regulation of β3-AR Expression,” Pnas 119 (2022): e2205626119.

[191] D. Xie, B. Stutz, F. Li, et al., “TET3 epigenetically Controls Feeding and Stress Response Behaviors via AGRP Neurons,” Journal of Clinical Investigation 132 (2022): e162365.

[192] G. W. Davison, R. E. Irwin, and C. P. Walsh, “The Metabolic-epigenetic Nexus in Type 2 Diabetes Mellitus,” Free Radical Biology & Medicine 170 (2021): 194-206.

[193] M. Xiao, H. Yang, W. Xu, et al., “Corrigendum: Inhibition of α-KG-dependent Histone and DNA Demethylases by Fumarate and Succinate That Are Accumulated in Mutations of FH and SDH Tumor Suppressors,” Genes & development 29 (2015): 887.

[194] S. Nosratabadi, D. Ashtary-Larky, F. Hosseini, et al., “The Effects of Vitamin C Supplementation on Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis,” Diabetes Metab Syndr 17 (2023): 102824.

[195] R. Yin, S. Mao, B. Zhao, et al., “Ascorbic Acid Enhances Tet-mediated 5-methylcytosine Oxidation and Promotes DNA Demethylation in Mammals,” Journal of the American Chemical Society 135 (2013): 10396-10403.

[196] N. Dhliwayo, M. P. Sarras, E. Luczkowski, S. M. Mason, and R. V. Intine, “Parp Inhibition Prevents Ten-eleven Translocase Enzyme Activation and Hyperglycemia-induced DNA Demethylation,” Diabetes 63 (2014): 3069-3076.

[197] J. Fuhrmeister, A. Zota, T. P. Sijmonsma, et al., “Fasting-induced Liver GADD45β Restrains Hepatic Fatty Acid Uptake and Improves Metabolic Health,” EMBO Molecular Medicine 8 (2016): 654-669.

[198] F. Spallotta, C. Cencioni, S. Atlante, et al., “Stable Oxidative Cytosine Modifications Accumulate in Cardiac Mesenchymal Cells From Type2 Diabetes Patients: Rescue by α-Ketoglutarate and TET-TDG Functional Reactivation,” Circulation Research 122 (2018): 31-46.

[199] A. Jangra, A. K. Datusalia, S. Khandwe, and S. S. Sharma, “Amelioration of Diabetes-induced Neurobehavioral and Neurochemical Changes by Melatonin and Nicotinamide: Implication of Oxidative Stress-PARP Pathway,” Pharmacology Biochemistry and Behavior 114-115 (2013): 43-51.

[200] Q. Yang, D. Fang, J. Chen, et al., “LncRNAs Associated with Oxidative Stress in Diabetic Wound Healing: Regulatory Mechanisms and Application Prospects,” Theranostics 13 (2023): 3655-3674.

[201] Y. An, B. Xu, S. Wan, et al., “The Role of Oxidative Stress in Diabetes Mellitus-induced Vascular Endothelial Dysfunction,” Cardiovasc Diabetol 22 (2023): 237.

[202] B. Delatte, J. Jeschke, M. Defrance, et al., “Genome-wide Hydroxymethylcytosine Pattern Changes in Response to Oxidative Stress,” Scientific Reports 5 (2015): 12714.

[203] K. Khunti, Y. V. Chudasama, E. W. Gregg, et al., “Diabetes and Multiple Long-term Conditions: A Review of Our Current Global Health Challenge,” Diabetes Care 46 (2023): 2092-2101.

[204] R. Suárez, S. P. Chapela, L. Álvarez-Córdova, et al., “Epigenetics in Obesity and Diabetes Mellitus: New Insights,” Nutrients 15 (2023), https://doi.org/10.3390/nu15040811.

[205] H. L. H. Green and A. C. Brewer, “Dysregulation of 2-oxoglutarate-dependent Dioxygenases by Hyperglycaemia: Does This Link Diabetes and Vascular Disease?,” Clinical Epigenetics 12 (2020): 59.

[206] S. Zhao, T. Jia, Y. Tang, et al., “Reduced mRNA and Protein Expression Levels of Tet Methylcytosine Dioxygenase 3 in Endothelial Progenitor Cells of Patients of Type 2 Diabetes with Peripheral Artery Disease,” Frontiers in immunology 9 (2018): 2859.

[207] L. Zhao, H. Xu, X. Liu, Y. Cheng, and J. Xie, “The Role of TET2-mediated ROBO4 Hypomethylation in the Development of Diabetic Retinopathy,” Journal of translational medicine 21 (2023): 455.

[208] R. A. Kowluru and Y. Shan, “Role of Oxidative Stress in Epigenetic Modification of MMP-9 Promoter in the Development of Diabetic Retinopathy,” Graefes Archive for Clinical and Experimental Ophthalmology 255 (2017): 955-962.

[209] Q. Ma, J. Gao, Q. Fan, et al., “Thinned Young Apple Polyphenols May Prevent Neuronal Apoptosis by Up-regulating 5-hydroxymethylcytosine in the Cerebral Cortex of High-fat Diet-induced Diabetic Mice,” Food Funct 14 (2023): 3279-3289.

[210] X. He, S. Pei, X. Meng, et al., “Punicalagin Attenuates Neuronal Apoptosis by Upregulating 5-Hydroxymethylcytosine in the Diabetic Mouse Brain,” Journal of Agricultural and Food Chemistry 70 (2022): 4995-5004.

[211] X. Liu, F. Liu, S. Gao, et al., “A Single Non-synonymous NCOA5 Variation in Type 2 Diabetic Patients With Hepatocellular Carcinoma Impairs the Function of NCOA5 in Cell Cycle Regulation,” Cancer Letters 391 (2017): 152-161.

[212] P. R. Keesari, A. Jain, N. R. Ganampet, et al., “Association Between Prediabetes and Breast Cancer: A Comprehensive Meta-analysis,” Breast Cancer Research and Treatment 204 (2024): 1-13.

[213] D. Wu, D. Hu, H. Chen, et al., “Glucose-regulated Phosphorylation of TET2 by AMPK Reveals a Pathway Linking Diabetes to Cancer,” Nature 559 (2018): 637-641.

[214] S. A. Ayodeji, B. Bao, E. A. Teslow, et al., “Hyperglycemia and O-GlcNAc Transferase Activity Drive a Cancer Stem Cell Pathway in Triple-negative Breast Cancer,” Cancer cell international 23 (2023): 102.

[215] A. Berthier, M. Vinod, G. Porez, et al., “Combinatorial Regulation of Hepatic Cytoplasmic Signaling and Nuclear Transcriptional Events by the OGT/REV-ERBα Complex,” Pnas 115 (2018): E11033-e11042.

[216] B. M. Veloso Pereira, M. Charleaux de Ponte, A. P. Malavolta Luz, and K. Thieme, “DNA Methylation Enzymes in the Kidneys of Male and Female BTBR Ob/Ob Mice,” Front Endocrinol (Lausanne) 14 (2023): 1167546.

[217] L. Yang, Q. Zhang, Q. Wu, et al., “Effect of TET2 on the Pathogenesis of Diabetic Nephropathy Through Activation of Transforming Growth Factor β1 Expression via DNA Demethylation,” Life Sciences 207 (2018): 127-137.

[218] B. Tampe, D. Tampe, C. A. Müller, et al., “Tet3-mediated Hydroxymethylation of Epigenetically Silenced Genes Contributes to Bone Morphogenic Protein 7-induced Reversal of Kidney Fibrosis,” Journal of the American Society of Nephrology 25 (2014): 905-912.

[219] B. Tampe, D. Tampe, E. M. Zeisberg, et al., “Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease,” EBioMedicine 2 (2015): 19-36.

[220] R. Dhat, D. Mongad, S. Raji, et al., “Epigenetic Modifier Alpha-ketoglutarate Modulates Aberrant Gene Body Methylation and Hydroxymethylation Marks in Diabetic Heart,” Epigenetics & chromatin 16 (2023): 12.

[221] S. Pei, H. Zhao, L. Chen, et al., “Preventive Effect of Ellagic Acid on Cardiac Dysfunction in Diabetic Mice Through Regulating DNA Hydroxymethylation,” Journal of Agricultural and Food Chemistry 70 (2022): 1902-1910.

[222] Q. Tan, W. Wang, C. Yang, et al., “α-ketoglutarate Is Associated With Delayed Wound Healing in Diabetes,” Clinical Endocrinology 85 (2016): 54-61.

[223] M. S. Diniz, U. Hiden, I. Falcão-Pires, P. J. Oliveira, L. Sobrevia, and S. P. Pereira, “Fetoplacental Endothelial Dysfunction in Gestational Diabetes Mellitus and Maternal Obesity: A Potential Threat for Programming Cardiovascular Disease,” Biochim Biophys Acta Mol Basis Dis 1869 (2023): 166834.

[224] W. L. Lowe, “Genetics and Epigenetics: Implications for the Life Course of Gestational Diabetes,” International Journal of Molecular Sciences 24 (2023), https://doi.org/10.3390/ijms24076047.

[225] M. Sun, M. M. Song, B. Wei, et al., “5-Hydroxymethylcytosine-mediated Alteration of Transposon Activity Associated With the Exposure to Adverse in Utero Environments in human,” Human Molecular Genetics 25 (2016): 2208-2219.

[226] J. Kusuyama, A. B. Alves-Wagner, R. H. Conlin, et al., “Placental Superoxide Dismutase 3 Mediates Benefits of Maternal Exercise on Offspring Health,” Cell metabolism 33 (2021): 939-956.e938.

[227] J. Hyun and Y. Jung, “DNA Methylation in Nonalcoholic Fatty Liver Disease,” International Journal of Molecular Sciences 21 (2020), https://doi.org/10.3390/ijms21218138.

[228] J. P. Thomson, J. M. Hunter, H. Lempiäinen, et al., “Dynamic Changes in 5-hydroxymethylation Signatures Underpin Early and Late Events in Drug Exposed Liver,” Nucleic Acids Res. 41 (2013): 5639-5654.

[229] M. J. Lyall, J. Cartier, J. P. Thomson, et al., “Modelling Non-alcoholic Fatty Liver Disease in human Hepatocyte-Like Cells,” Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 373 (2018), https://doi.org/10.1098/rstb.2017.0362.

[230] Y. Yuan, C. Liu, X. Chen, et al., “Vitamin C Inhibits the Metabolic Changes Induced by Tet1 Insufficiency under High Fat Diet Stress,” Molecular Nutrition & Food Research 65 (2021): e2100417.

[231] A. Page, P. Paoli, E. Moran Salvador, S. White, J. French, and J. Mann, “Hepatic Stellate Cell Transdifferentiation Involves Genome-wide Remodeling of the DNA Methylation Landscape,” Journal of Hepatology 64 (2016): 661-673.

[232] M. Zeybel, T. Hardy, S. M. Robinson, et al., “Differential DNA Methylation of Genes Involved in Fibrosis Progression in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease,” Clinical Epigenetics 7 (2015): 25.

[233] C. Theys, D. Lauwers, C. Perez-Novo, and W. Vanden Berghe, “PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?,” Biomedicines 10 (2022), https://doi.org/10.3390/biomedicines10123041.

[234] C. J. Pirola, R. Scian, T. F. Gianotti, et al., “Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins,” Medicine 94 (2015): e1480.

[235] Z. Lai, J. Chen, C. Ding, et al., “Association of Hepatic Global DNA Methylation and Serum One-Carbon Metabolites With Histological Severity in Patients With NAFLD,” Obesity (Silver Spring) 28 (2020): 197-205.

[236] J. Lee, J. Song, J. Park, et al., “Dnmt1/Tet2-mediated Changes in Cmip Methylation Regulate the Development of Nonalcoholic Fatty Liver Disease by Controlling the Gbp2-Pparγ-CD36 Axis,” Experimental & Molecular Medicine 55 (2023): 143-157.

[237] M. Vachher, S. Bansal, B. Kumar, S. Yadav, and A. Burman, “Deciphering the Role of Aberrant DNA Methylation in NAFLD and NASH,” Heliyon 8 (2022): e11119.

[238] H. Kim, O. Worsley, E. Yang, et al., “Persistent Changes in Liver Methylation and Microbiome Composition Following Reversal of Diet-induced Non-alcoholic-fatty Liver Disease,” Cellular and Molecular Life Sciences 76 (2019): 4341-4354.

[239] J. A. Oben, A. Mouralidarane, A. Samuelsson, et al., “Maternal Obesity During Pregnancy and Lactation Programs the Development of Offspring Non-alcoholic Fatty Liver Disease in Mice,” Journal of Hepatology 52 (2010): 913-920.

[240] M. G. M. Pruis, Á. Lendvai, V. W. Bloks, et al., “Maternal Western Diet Primes Non-alcoholic Fatty Liver Disease in Adult Mouse Offspring,” Acta Physiol (Oxf) 210 (2014): 215-227.

[241] M. Ko, J. An, W. A. Pastor, S. B. Koralov, K. Rajewsky, and A. Rao, “TET Proteins and 5-methylcytosine Oxidation in Hematological Cancers,” Immunological Reviews 263 (2015): 6-21.

[242] T. Dziaman, D. Gackowski, J. Guz, et al., “Characteristic Profiles of DNA Epigenetic Modifications in Colon Cancer and Its Predisposing Conditions-benign Adenomas and Inflammatory Bowel Disease,” Clinical Epigenetics 10 (2018): 72.

[243] S. Uribe-Lewis, R. Stark, T. Carroll, et al., “5-hydroxymethylcytosine Marks Promoters in Colon That Resist DNA Hypermethylation in Cancer,” Genome biology 16 (2015): 69.

[244] J. Wu, H. Li, M. Shi, et al., “TET1-mediated DNA Hydroxymethylation Activates Inhibitors of the Wnt/β-catenin Signaling Pathway to Suppress EMT in Pancreatic Tumor Cells,” Journal of Experimental & Clinical Cancer Research 38 (2019): 348.

[245] M. Deng, R. Zhang, Z. He, et al., “TET-Mediated Sequestration of miR-26 Drives EZH2 Expression and Gastric Carcinogenesis,” Cancer Research 77 (2017): 6069-6082.

[246] C. Du, N. Kurabe, Y. Matsushima, et al., “Robust Quantitative Assessments of Cytosine Modifications and Changes in the Expressions of Related Enzymes in Gastric Cancer,” Gastric Cancer 18 (2015): 516-525.

[247] H. Yang, Y. Liu, F. Bai, et al., “Tumor Development Is Associated With Decrease of TET Gene Expression and 5-methylcytosine Hydroxylation,” Oncogene 32 (2013): 663-669.

[248] M. L. Nickerson, S. Das, K. M. Im, et al., “TET2 binds the Androgen Receptor and Loss Is Associated With Prostate Cancer,” Oncogene 36 (2017): 2172-2183.

[249] L. Chen, R. Huang, M. W. Chan, et al., “TET1 reprograms the Epithelial Ovarian Cancer Epigenome and Reveals Casein Kinase 2α as a Therapeutic Target,” Journal of Pathology 248 (2019): 363-376.

[250] Q. Chen, D. Yin, Y. Zhang, et al., “MicroRNA-29a Induces Loss of 5-hydroxymethylcytosine and Promotes Metastasis of Hepatocellular Carcinoma Through a TET-SOCS1-MMP9 Signaling Axis,” Cell death & disease 8 (2017): e2906.

[251] X. Bai, H. Zhang, Y. Zhou, et al., “Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma with Wild-Type Isocitrate Dehydrogenase 1,” Hepatology 73 (2021): 1747-1763.

[252] A. Brągiel-Pieczonka, G. Lipka, A. Stapińska-Syniec, et al., “The Profiles of Tet-Mediated DNA Hydroxymethylation in Human Gliomas,” Frontiers in oncology 12 (2022): 621460.

[253] Q. Xu, C. Wang, J. X. Zhou, et al., “Loss of TET Reprograms Wnt Signaling Through Impaired Demethylation to Promote Lung Cancer Development,” Pnas 119 (2022): e2107599119.

[254] Y. Xu, L. Lv, Y. Liu, et al., “Tumor Suppressor TET2 Promotes Cancer Immunity and Immunotherapy Efficacy,” Journal of Clinical Investigation 129 (2019): 4316-4331.

[255] W. Liu, G. Wu, F. Xiong, and Y. Chen, “Advances in the DNA Methylation Hydroxylase TET1,” Biomarker Research 9 (2021): 76.

[256] M. Benvenuto, C. Focaccetti, V. Izzi, L. Masuelli, A. Modesti, and R. Bei, “Tumor Antigens Heterogeneity and Immune Response-targeting Neoantigens in Breast Cancer,” Seminars in Cancer Biology 72 (2021): 65-75.

[257] M. C. Haffner, A. Chaux, A. K. Meeker, et al., “Global 5-hydroxymethylcytosine Content Is Significantly Reduced in Tissue Stem/Progenitor Cell Compartments and in human Cancers,” Oncotarget 2 (2011): 627-637.

[258] C. R. Good, S. Panjarian, A. D. Kelly, et al., “TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer,” Cancer Research 78 (2018): 4126-4137.

[259] Z. Li, C. Lyu, Y. Ren, and H. Wang, “Role of TET Dioxygenases and DNA Hydroxymethylation in Bisphenols-Stimulated Proliferation of Breast Cancer Cells,” Environmental Health Perspectives 128 (2020): 27008.

[260] B. Bao, E. A. Teslow, C. Mitrea, J. L. Boerner, G. Dyson, and A. Bollig-Fischer, “Role of TET1 and 5hmC in an Obesity-Linked Pathway Driving Cancer Stem Cells in Triple-Negative Breast Cancer,” Molecular Cancer Research 18 (2020): 1803-1814.

[261] Y. Yu, J. Qi, J. Xiong, et al., “Epigenetic Co-Deregulation of EZH2/TET1 Is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer,” Theranostics 9 (2019): 761-777.

[262] C. Hsu, K. Peng, M. Kang, et al., “TET1 suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases,” Cell reports 2 (2012): 568-579.

[263] E. Collignon, A. Canale, C. Al Wardi, et al., “Immunity Drives TET1 Regulation in Cancer Through NF-κB,” Science Advances 4 (2018): eaap7309.

[264] M. Sun, C. Song, H. Huang, et al., “HMGA2/TET1/HOXA9 signaling Pathway Regulates Breast Cancer Growth and Metastasis,” Pnas 110 (2013): 9920-9925.

[265] Y. F. Pei, Y. Lei, and X. Q. Liu, “MiR-29a Promotes Cell Proliferation and EMT in Breast Cancer by Targeting Ten Eleven Translocation 1,” Biochimica Et Biophysica Acta 1862 (2016): 2177-2185.

[266] S. Song, L. Poliseno, M. Song, et al., “MicroRNA-antagonism Regulates Breast Cancer Stemness and Metastasis via TET-family-dependent Chromatin Remodeling,” Cell 154 (2013): 311-324.

[267] M. Pagliuca, M. Donato, A. L. D'Amato, et al., “New Steps on an Old Path: Novel Estrogen Receptor Inhibitors in Breast Cancer,” Critical Reviews in Oncology/Hematology 180 (2022): 103861.

[268] C. Corti, C. De Angelis, G. Bianchini, et al., “Novel Endocrine Therapies: What Is next in Estrogen Receptor Positive, HER2 Negative Breast Cancer?,” Cancer Treatment Reviews 117 (2023): 102569.

[269] A. Sklias, A. Halaburkova, L. Vanzan, et al., “Epigenetic Remodelling of Enhancers in Response to Estrogen Deprivation and Re-stimulation,” Nucleic Acids Res. 49 (2021): 9738-9754.

[270] L. Wang, P. A. Ozark, E. R. Smith, et al., “TET2 coactivates Gene Expression Through Demethylation of Enhancers,” Science Advances 4 (2018): eaau6986.

[271] M. R. Kim, M. J. Wu, Y. Zhang, J. Y. Yang, and C. J. Chang, “TET2 directs Mammary Luminal Cell Differentiation and Endocrine Response,” Nature Communications 11 (2020): 4642.

[272] X. Zhang, L. Shi, H. Sun, et al., “IGF2BP3 mediates the mRNA Degradation of NF1 to Promote Triple-negative Breast Cancer Progression via an m6A-dependent Manner,” Clinical and translational medicine 13 (2023): e1427.

[273] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer Statistics, 2021,” CA: A Cancer Journal for Clinicians 71 (2021): 7-33.

[274] E. B. Conemans, L. Lodewijk, C. B. Moelans, et al., “DNA Methylation Profiling in MEN1-related Pancreatic Neuroendocrine Tumors Reveals a Potential Epigenetic Target for Treatment,” European Journal of Endocrinology 179 (2018): 153-160.

[275] M. T. T. Roalsø, Ø. H. Hald, M. Alexeeva, and K. Søreide, “Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma,” Cancers (Basel) 14 (2022): 546.

[276] H. Li, W. Jiang, X. Liu, et al., “TET1 downregulates Epithelial-mesenchymal Transition and Chemoresistance in PDAC by Demethylating CHL1 to Inhibit the Hedgehog Signaling Pathway,” Oncogene 39 (2020): 5825-5838.

[277] Y. Huang, W. Hong, and X. Wei, “The Molecular Mechanisms and Therapeutic Strategies of EMT in Tumor Progression and Metastasis,” Journal of hematology & oncology 15 (2022): 129.

[278] T. D. Bhagat, D. Von Ahrens, M. Dawlaty, et al., “Lactate-mediated Epigenetic Reprogramming Regulates Formation of human Pancreatic Cancer-associated Fibroblasts,” Elife 8 (2019), https://doi.org/10.7554/eLife.50663.

[279] X. Ren, J. Yan, Q. Zhao, et al., “The Fe-S Cluster Assembly Protein IscU2 Increases α-ketoglutarate Catabolism and DNA 5mC to Promote Tumor Growth,” Cell Discovery 9 (2023): 76.

[280] L. Xu, X. Ma, X. Zhang, et al., “hsa_circ_0007919 induces LIG1 Transcription by Binding to FOXA1/TET1 to Enhance the DNA Damage Response and Promote Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma,” Molecular cancer 22 (2023): 195.

[281] J. P. Thomson, R. Ottaviano, E. B. Unterberger, et al., “Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant With Aberrant Promoter Hypermethylation in Liver Cancer,” Cancer Research 76 (2016): 3097-3108.

[282] J. Liu, J. Jiang, J. Mo, et al., “Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma,” Hepatology 69 (2019): 196-208.

[283] F. Gao, Y. Xia, J. Wang, et al., “Integrated Analyses of DNA Methylation and Hydroxymethylation Reveal Tumor Suppressive Roles of ECM1, ATF5, and EOMES in human Hepatocellular Carcinoma,” Genome biology 15 (2014): 533.

[284] P. Wang, Y. Yan, W. Yu, and H. Zhang, “Role of Ten-eleven Translocation Proteins and 5-hydroxymethylcytosine in Hepatocellular Carcinoma,” Cell Proliferation 52 (2019): e12626.

[285] H. Chen, W. Cai, E. S. H. Chu, et al., “Hepatic Cyclooxygenase-2 Overexpression Induced Spontaneous Hepatocellular Carcinoma Formation in Mice,” Oncogene 36 (2017): 4415-4426.

[286] K. Chuang, C. L. Whitney-Miller, C. Chu, et al., “MicroRNA-494 Is a Master Epigenetic Regulator of Multiple Invasion-suppressor microRNAs by Targeting Ten Eleven Translocation 1 in Invasive human Hepatocellular Carcinoma Tumors,” Hepatology 62 (2015): 466-480.

[287] L. L. Lin, W. Wang, Z. Hu, L. W. Wang, J. Chang, and H. Qian, “Erratum to: Negative Feedback of miR-29 family TET1 Involves in Hepatocellular Cancer,” Medical Oncology 32 (2015): 39.

[288] W. Zhang, Z. Lu, Y. Gao, L. Ye, T. Song, and X. Zhang, “MiR-520b Suppresses Proliferation of Hepatoma Cells Through Targeting Ten-eleven Translocation 1 (TET1) mRNA,” Biochemical and Biophysical Research Communications 460 (2015): 793-798.

[289] L. Cao, X. Yang, Y. Chen, D. Zhang, X. Jiang, and P. Xue, “Exosomal miR-21 Regulates the TETs/PTENp1/PTEN Pathway to Promote Hepatocellular Carcinoma Growth,” Molecular cancer 18 (2019): 148.

[290] Z. Dong, A. Ke, T. Li, et al., “CircMEMO1 modulates the Promoter Methylation and Expression of TCF21 to Regulate Hepatocellular Carcinoma Progression and Sorafenib Treatment Sensitivity,” Molecular cancer 20 (2021): 75.

[291] S. O. Sajadian, S. Ehnert, H. Vakilian, et al., “Induction of Active Demethylation and 5hmC Formation by 5-azacytidine Is TET2 Dependent and Suggests New Treatment Strategies Against Hepatocellular Carcinoma,” Clinical Epigenetics 7 (2015): 98.

[292] L. H. Biller and D. Schrag, “Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review,” Jama 325 (2021): 669-685.

[293] R. Tricarico, J. Madzo, G. Scher, et al., “TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors with the CpG Island Methylator Phenotype,” Gastroenterology 164 (2023): 921-936.e921.

[294] B. Ndreshkjana, A. Çapci, V. Klein, et al., “Combination of 5-fluorouracil and Thymoquinone Targets Stem Cell Gene Signature in Colorectal Cancer Cells,” Cell death & disease 10 (2019): 379.

[295] B. C. He, J. L. Gao, X. Luo, et al., “Ginsenoside Rg3 Inhibits Colorectal Tumor Growth Through the Down-regulation of Wnt/Ss-catenin Signaling,” International Journal of Oncology 38 (2011): 437-445.

[296] F. Neri, D. Dettori, D. Incarnato, et al., “TET1 is a Tumour Suppressor That Inhibits Colon Cancer Growth by Derepressing Inhibitors of the WNT Pathway,” Oncogene 34 (2015): 4168-4176.

[297] K. A. Kang, M. J. Piao, K. C. Kim, et al., “Epigenetic Modification of Nrf2 in 5-fluorouracil-resistant Colon Cancer Cells: Involvement of TET-dependent DNA Demethylation,” Cell death & disease 5 (2014): e1183.

[298] L. R. Schaff and I. K. Mellinghoff, “Glioblastoma and Other Primary Brain Malignancies in Adults: A Review,” Jama 329 (2023): 574-587.

[299] A. Carella, J. R. Tejedor, M. G. García, et al., “Epigenetic Downregulation of TET3 Reduces Genome-wide 5hmC Levels and Promotes Glioblastoma Tumorigenesis,” International Journal of Cancer 146 (2020): 373-387.

[300] H. Lopez-Bertoni, A. Johnson, Y. Rui, et al., “Sox2 induces Glioblastoma Cell Stemness and Tumor Propagation by Repressing TET2 and Deregulating 5hmC and 5mC DNA Modifications,” Signal Transduction and Targeted Therapy 7 (2022): 37.

[301] T. F. J. Kraus, G. Kolck, A. Greiner, K. Schierl, V. Guibourt, and H. A. Kretzschmar, “Loss of 5-hydroxymethylcytosine and Intratumoral Heterogeneity as an Epigenomic Hallmark of Glioblastoma,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 36 (2015): 8439-8446.

[302] B. A. Orr, M. C. Haffner, W. G. Nelson, S. Yegnasubramanian, and C. G. Eberhart, “Decreased 5-hydroxymethylcytosine Is Associated With Neural Progenitor Phenotype in Normal Brain and Shorter Survival in Malignant Glioma,” PLoS ONE 7 (2012): e41036.

[303] M. S. Waitkus, B. H. Diplas, and H. Yan, “Isocitrate Dehydrogenase Mutations in Gliomas,” Neuro-oncol 18 (2016): 16-26.

[304] M. E. Figueroa, O. Abdel-Wahab, C. Lu, et al., “Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation,” Cancer Cell 18 (2010): 553-567.

[305] P. Boskovic, N. Wilke, K. Man, P. Lichter, L. Francois, and B. Radlwimmer, “Branched-chain Amino Acid Transaminase 1 Regulates Glioblastoma Cell Plasticity and Contributes to Immunosuppression,” Neuro-oncol 26 (2024): 251-265.

[306] M. Forloni, R. Gupta, A. Nagarajan, et al., “Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells,” Cell reports 16 (2016): 457-471.

[307] C. J. Mariani, A. Vasanthakumar, J. Madzo, et al., “TET1-mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma,” Cell reports 7 (2014): 1343-1352.

[308] H. J. Yun, M. Li, D. Guo, et al., “AMPK-HIF-1α Signaling Enhances Glucose-derived De Novo Serine Biosynthesis to Promote Glioblastoma Growth,” Journal of Experimental & Clinical Cancer Research 42 (2023): 340.

[309] D. Boso, E. Rampazzo, C. Zanon, et al., “HIF-1α/Wnt Signaling-dependent Control of Gene Transcription Regulates Neuronal Differentiation of Glioblastoma Stem Cells,” Theranostics 9 (2019): 4860-4877.

[310] S. Ren and Y. Xu, “AC016405.3, a Novel Long Noncoding RNA, Acts as a Tumor Suppressor Through Modulation of TET2 by microRNA-19a-5p Sponging in Glioblastoma,” Cancer Science 110 (2019): 1621-1632.

[311] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71 (2021): 209-249.

[312] X. Li, Y. Liu, T. Salz, K. D. Hansen, and A. Feinberg, “Whole-genome Analysis of the Methylome and Hydroxymethylome in Normal and Malignant Lung and Liver,” Genome Research 26 (2016): 1730-1741.

[313] P. T. Filipczak, S. Leng, C. S. Tellez, et al., “p53-Suppressed Oncogene TET1 Prevents Cellular Aging in Lung Cancer,” Cancer Research 79 (2019): 1758-1768.

[314] H. Q. Chen, D. J. Chen, Y. Li, et al., “Epigenetic Silencing of TET1 Mediated Hydroxymethylation of Base Excision Repair Pathway During Lung Carcinogenesis,” Environmental Pollution 268 (2021): 115860.

[315] S. Goel, V. Bhatia, T. Biswas, and B. Ateeq, “Epigenetic Reprogramming During Prostate Cancer Progression: A Perspective From Development,” Seminars in Cancer Biology 83 (2022): 136-151.

[316] E. Smeets, A. G. Lynch, S. Prekovic, et al., “The Role of TET-mediated DNA Hydroxymethylation in Prostate Cancer,” Molecular and Cellular Endocrinology 462 (2018): 41-55.

[317] M. Fraser, V. Y. Sabelnykova, T. N. Yamaguchi, et al., “Genomic Hallmarks of Localized, Non-indolent Prostate Cancer,” Nature 541 (2017): 359-364.

[318] L. Spans, T. Van Den Broeck, E. Smeets, et al., “Genomic and Epigenomic Analysis of High-risk Prostate Cancer Reveals Changes in Hydroxymethylation and TET1,” Oncotarget 7 (2016): 24326-24338.

[319] D. Westaby, M. D. L. D. Fenor De La Maza, A. Paschalis, et al., “A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer,” Annual Review of Pharmacology and Toxicology 62 (2022): 131-153.

[320] K.-I. Takayama, A. Misawa, T. Suzuki, et al., “TET2 repression by Androgen Hormone Regulates Global Hydroxymethylation Status and Prostate Cancer Progression,” Nature Communications 6 (2015): 8219.

[321] D. Liu, Y. Liu, W. Zhu, et al., “Helicobacter pylori-induced Aberrant Demethylation and Expression of GNB4 Promotes Gastric Carcinogenesis via the Hippo-YAP1 Pathway,” BMC Medicine [Electronic Resource] 21 (2023): 134.

[322] T. L. Cover, D. B. Lacy, and M. D. Ohi, “The Helicobacter pylori Cag Type IV Secretion System,” Trends in Microbiology 28 (2020): 682-695.

[323] L. Shi, J. Shangguan, Y. Lu, et al., “ROS-mediated Up-regulation of SAE1 by Helicobacter pylori Promotes human Gastric Tumor Genesis and Progression,” Journal of translational medicine 22 (2024): 148.

[324] N. Godbole, A. Quinn, F. Carrion, E. Pelosi, and C. Salomon, “Extracellular Vesicles as a Potential Delivery Platform for CRISPR-Cas Based Therapy in Epithelial Ovarian Cancer,” Seminars in Cancer Biology 96 (2023): 64-81.

[325] H. Duan, Z. Yan, W. Chen, et al., “TET1 inhibits EMT of Ovarian Cancer Cells Through Activating Wnt/β-catenin Signaling Inhibitors DKK1 and SFRP2,” Gynecologic Oncology 147 (2017): 408-417.

[326] Z. Ye, J. Li, X. Han, et al., “TET3 inhibits TGF-β1-induced Epithelial-mesenchymal Transition by Demethylating miR-30d Precursor Gene in Ovarian Cancer Cells,” Journal of Experimental & Clinical Cancer Research 35 (2016): 72.

[327] H. Li, Z.-Q. Zhou, Z.-R. Yang, et al., “MicroRNA-191 Acts as a Tumor Promoter by Modulating the TET1-p53 Pathway in Intrahepatic Cholangiocarcinoma,” Hepatology 66 (2017): 136-151.

[328] K. Sideeq Bhat, H. Kim, A. Alam, M. Ko, J. An, and S. Lim, “Rapid and Label-Free Detection of 5-Hydroxymethylcytosine in Genomic DNA Using an Au/ZnO Nanorods Hybrid Nanostructure-Based Electrochemical Sensor,” Advanced Healthcare Materials 10 (2021): e2101193.

[329] Q. Yang, H. Dang, J. Liu, et al., “Hypoxia Switches TET1 From Being Tumor-suppressive to Oncogenic,” Oncogene 42 (2023): 1634-1648.

[330] L. Scourzic, E. Mouly, and O. A. Bernard, “TET Proteins and the Control of Cytosine Demethylation in Cancer,” Genome Medicine 7 (2015): 9.

[331] K. Joshi, L. Zhang, P. Breslin SJ, A. R. Kini, and J. Zhang, “Role of TET Dioxygenases in the Regulation of both Normal and Pathological Hematopoiesis,” Journal of Experimental & Clinical Cancer Research 41 (2022): 294.

[332] E. Solary, O. A. Bernard, A. Tefferi, F. Fuks, and W. Vainchenker, “The Ten-Eleven Translocation-2 (TET2) Gene in Hematopoiesis and Hematopoietic Diseases,” Leukemia 28 (2014): 485-496.

[333] J. Xie, M. Sheng, S. Rong, et al., “STING Activation in TET2-mutated Hematopoietic Stem/Progenitor Cells Contributes to the Increased Self-renewal and Neoplastic Transformation,” Leukemia 37 (2023): 2457-2467.

[334] S. Jaiswal and B. L. Ebert, “Clonal Hematopoiesis in human Aging and Disease,” Science 366 (2019), https://doi.org/10.1126/science.aan4673.

[335] M. Jan, B. L. Ebert, and S. Jaiswal, “Clonal Hematopoiesis,” Seminars in Hematology 54 (2017): 43-50.

[336] C. C. Coombs, A. Zehir, S. M. Devlin, et al., “Therapy-Related Clonal Hematopoiesis in Patients With Non-hematologic Cancers Is Common and Associated With Adverse Clinical Outcomes,” Cell Stem Cell 21 (2017): 374-382.e374.

[337] H. Awada, Y. Nagata, A. Goyal, et al., “Invariant Phenotype and Molecular Association of Biallelic TET2 Mutant Myeloid Neoplasia,” Blood Advances 3 (2019): 339-349.

[338] M. Bensberg, O. Rundquist, A. Selimović, et al., “TET2 as a Tumor Suppressor and Therapeutic Target in T-cell Acute Lymphoblastic Leukemia,” Pnas 118 (2021), https://doi.org/10.1073/pnas.2110758118.

[339] F. Delhommeau, S. Dupont, V. D. Valle, et al., “Mutation in TET2 in Myeloid Cancers,” New England Journal of Medicine 360 (2009): 2289-2301.

[340] O. Kosmider, V. Gelsi-Boyer, M. Ciudad, et al., “TET2 gene Mutation Is a Frequent and Adverse Event in Chronic Myelomonocytic Leukemia,” Haematologica 94 (2009): 1676-1681.

[341] O. Kosmider, V. Gelsi-Boyer, M. Cheok, et al., “TET2 mutation Is an Independent Favorable Prognostic Factor in Myelodysplastic Syndromes (MDSs),” Blood 114 (2009): 3285-3291.

[342] A. E. Smith, A. M. Mohamedali, A. Kulasekararaj, et al., “Next-generation Sequencing of the TET2 Gene in 355 MDS and CMML Patients Reveals Low-abundance Mutant Clones With Early Origins, but Indicates no Definite Prognostic Value,” Blood 116 (2010): 3923-3932.

[343] S. Weissmann, T. Alpermann, V. Grossmann, et al., “Landscape of TET2 Mutations in Acute Myeloid Leukemia,” Leukemia 26 (2012): 934-942.

[344] A. Tefferi, H. Alkhateeb, and N. Gangat, “Blast Phase Myeloproliferative Neoplasm: Contemporary Review and 2024 Treatment Algorithm,” Blood cancer journal 13 (2023): 108.

[345] M. M. Patnaik and A. Tefferi, “Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification, and Management,” American Journal of Hematology 97 (2022): 352-372.

[346] C. Quivoron, L. Couronné, V. Della Valle, et al., “TET2 inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event During human Lymphomagenesis,” Cancer Cell 20 (2011): 25-38.

[347] O. Abdel-Wahab, A. Mullally, C. Hedvat, et al., “Genetic Characterization of TET1, TET2, and TET3 Alterations in Myeloid Malignancies,” Blood 114 (2009): 144-147.

[348] A. Zhao, H. Zhou, J. Yang, M. Li, and T. Niu, “Epigenetic Regulation in Hematopoiesis and Its Implications in the Targeted Therapy of Hematologic Malignancies,” Signal Transduction and Targeted Therapy 8 (2023): 71.

[349] S. Chiba, “Dysregulation of TET2 in Hematologic Malignancies,” International Journal of Hematology 105 (2017): 17-22.

[350] C. Li, J. He, F. Meng, et al., “Nuclear Localization of TET2 Requires β-catenin Activation and Correlates With Favourable Prognosis in Colorectal Cancer,” Cell death & disease 14 (2023): 552.

[351] J. R. Shingleton and S. S. Dave, “TET2 Deficiency Sets the Stage for B-cell Lymphoma,” Cancer discovery 8 (2018): 1515-1517.

[352] S. Jaiswal, P. Fontanillas, J. Flannick, et al., “Age-related Clonal Hematopoiesis Associated With Adverse Outcomes,” New England Journal of Medicine 371 (2014): 2488-2498.

[353] W. J. Wong, C. Emdin, A. G. Bick, et al., “Clonal Haematopoiesis and Risk of Chronic Liver Disease,” Nature 616 (2023): 747-754.

[354] P. Lundberg, A. Karow, R. Nienhold, et al., “Clonal Evolution and Clinical Correlates of Somatic Mutations in Myeloproliferative Neoplasms,” Blood 123 (2014): 2220-2228.

[355] T. Haferlach, Y. Nagata, V. Grossmann, et al., “Landscape of Genetic Lesions in 944 Patients With Myelodysplastic Syndromes,” Leukemia 28 (2014): 241-247.

[356] J. Xu, F. Song, H. Lyu, et al., “Subtype-specific 3D Genome Alteration in Acute Myeloid Leukaemia,” Nature 611 (2022): 387-398.

[357] J. P. Vaque, N. Martinez, A. Batlle-Lopez, et al., “B-cell Lymphoma Mutations: Improving Diagnostics and Enabling Targeted Therapies,” Haematologica 99 (2014): 222-231.

[358] J. Choi, G. Goh, T. Walradt, et al., “Genomic Landscape of Cutaneous T Cell Lymphoma,” Nature Genetics 47 (2015): 1011-1019.

[359] E. Bachy, M. Urb, S. Chandra, et al., “CD1d-restricted Peripheral T Cell Lymphoma in Mice and Humans,” Journal of Experimental Medicine 213 (2016): 841-857.

[360] M. Sánchez-Beato, M. Méndez, M. Guirado, et al., “A Genetic Profiling Guideline to Support Diagnosis and Clinical Management of Lymphomas,” Clinical & translational oncology 26 (2024): 1043-1062.

[361] S. Y. Ng, L. Brown, K. Stevenson, et al., “RhoA G17V Is Sufficient to Induce Autoimmunity and Promotes T-cell Lymphomagenesis in Mice,” Blood 132 (2018): 935-947.

[362] J. R. Cortes, A. Ambesi-Impiombato, L. Couronné, et al., “RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis,” Cancer Cell 33 (2018): 259-273.e257.

[363] B. Yu, M. B. Roberts, L. M. Raffield, et al., “Supplemental Association of Clonal Hematopoiesis with Incident Heart Failure,” Journal of the American College of Cardiology 78 (2021): 42-52.

[364] J. J. Fuster, S. MacLauchlan, M. A. Zuriaga, et al., “Clonal Hematopoiesis Associated With TET2 Deficiency Accelerates Atherosclerosis Development in Mice,” Science 355 (2017): 842-847.

[365] A. A. Z. Dawoud, R. D. Gilbert, W. J. Tapper, and N. C. P. Cross, “Clonal Myelopoiesis Promotes Adverse Outcomes in Chronic Kidney Disease,” Leukemia 36 (2022): 507-515.

[366] M. A. Florez, B. T. Tran, T. K. Wathan, J. DeGregori, E. M. Pietras, and K. Y. King, “Clonal Hematopoiesis: Mutation-specific Adaptation to Environmental Change,” Cell Stem Cell 29 (2022): 882-904.

[367] M. A. Evans and K. Walsh, “Clonal Hematopoiesis, Somatic Mosaicism, and Age-associated Disease,” Physiological Reviews 103 (2023): 649-716.

[368] W. Xu, H. Yang, Y. Liu, et al., “Oncometabolite 2-hydroxyglutarate Is a Competitive Inhibitor of α-ketoglutarate-dependent Dioxygenases,” Cancer Cell 19 (2011): 17-30.

[369] R. Rampal, A. Alkalin, J. Madzo, et al., “DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia,” Cell reports 9 (2014): 1841-1855.

[370] Y. Wang, M. Xiao, X. Chen, et al., “WT1 recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation,” Molecular Cell 57 (2015): 662-673.

[371] M. Meisel, R. Hinterleitner, A. Pacis, et al., “Microbial Signals Drive Pre-leukaemic Myeloproliferation in a Tet2-deficient Host,” Nature 557 (2018): 580-584.

[372] Z. Cai, J. J. Kotzin, B. Ramdas, et al., “Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis,” Cell Stem Cell 23 (2018): 833-849.e835.

[373] P. M. Dominguez, H. Ghamlouch, W. Rosikiewicz, et al., “TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis,” Cancer discovery 8 (2018): 1632-1653.

[374] M. A. Mintz and J. G. Cyster, “T Follicular Helper Cells in Germinal Center B Cell Selection and Lymphomagenesis,” Immunological Reviews 296 (2020): 48-61.

[375] L. Duan, D. Liu, H. Chen, et al., “Follicular Dendritic Cells Restrict Interleukin-4 Availability in Germinal Centers and Foster Memory B Cell Generation,” Immunity 54 (2021): 2256-2272.e2256.

[376] E. Mouly, H. Ghamlouch, V. Della-Valle, et al., “B-cell Tumor Development in Tet2-deficient Mice,” Blood Advances 2 (2018): 703-714.

[377] M. Rodríguez, R. Alonso-Alonso, L. Tomás-Roca, et al., “Peripheral T-cell Lymphoma: Molecular Profiling Recognizes Subclasses and Identifies Prognostic Markers,” Blood Advances 5 (2021): 5588-5598.

[378] T. B. Nguyen, M. Sakata-Yanagimoto, M. Fujisawa, et al., “Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma,” Cancer Research 80 (2020): 1875-1884.

[379] F. Que, L. Zhang, T. Wang, M. Xu, W. Li, and S. Zang, “RHOA G17V Induces T Follicular Helper Cell Specification and Involves Angioimmunoblastic T-cell Lymphoma via Upregulating the Expression of PON2 Through an NF-κB-dependent Mechanism,” Oncoimmunology 11 (2022): 2134536.

[380] C. J. Lio, H. Yuita, and A. Rao, “Dysregulation of the TET family of Epigenetic Regulators in Lymphoid and Myeloid Malignancies,” Blood 134 (2019): 1487-1497.

[381] M. Fujisawa, T. B. Nguyen, Y. Abe, et al., “Clonal Germinal Center B Cells Function as a Niche for T-cell Lymphoma,” Blood 140 (2022): 1937-1950.

[382] C. Wang, T. W. McKeithan, Q. Gong, et al., “IDH2R172 mutations Define a Unique Subgroup of Patients With Angioimmunoblastic T-cell Lymphoma,” Blood 126 (2015): 1741-1752.

[383] F. Lemonnier, R. A. Cairns, S. Inoue, et al., “The IDH2 R172K Mutation Associated With Angioimmunoblastic T-cell Lymphoma Produces 2HG in T Cells and Impacts Lymphoid Development,” Pnas 113 (2016): 15084-15089.

[384] F. Stölzel, S. E. Fordham, D. Nandana, et al., “Biallelic TET2 Mutations Confer Sensitivity to 5'-azacitidine in Acute Myeloid Leukemia,” JCI Insight 8 (2023), https://doi.org/10.1172/jci.insight.150368.

[385] L. Morinishi, K. Kochanowski, R. L. Levine, L. F. Wu, and S. J. Altschuler, “Loss of TET2 Affects Proliferation and Drug Sensitivity Through Altered Dynamics of Cell-State Transitions,” Cell Systems 11 (2020): 86-94.e85.

[386] X. Hu, K. Luo, H. Shi, et al., “Integrated 5-hydroxymethylcytosine and Fragmentation Signatures as Enhanced Biomarkers in Lung Cancer,” Clinical Epigenetics 14 (2022): 15.

[387] J. Li, S. Zhao, M. Lee, et al., “Reliable Tumor Detection by Whole-genome Methylation Sequencing of Cell-free DNA in Cerebrospinal Fluid of Pediatric Medulloblastoma,” Science Advances 6 (2020), https://doi.org/10.1126/sciadv.abb5427.

[388] E. B. Fabyanic, P. Hu, Q. Qiu, et al., “Joint Single-cell Profiling Resolves 5mC and 5hmC and Reveals Their Distinct Gene Regulatory Effects,” Nature Biotechnology 42, no. 6 (2023): 960-974.

[389] V. López, A. F. Fernández, and M. F. Fraga, “The Role of 5-hydroxymethylcytosine in Development, Aging and Age-related Diseases,” Ageing Research Reviews 37 (2017): 28-38.

[390] B. Thienpont, J. Steinbacher, H. Zhao, et al., “Tumour Hypoxia Causes DNA Hypermethylation by Reducing TET Activity,” Nature 537 (2016): 63-68.

[391] P. Koivunen and T. Laukka, “The TET Enzymes,” Cellular and Molecular Life Sciences 75 (2018): 1339-1348.

[392] E. Kriukienė, M. Tomkuvienė, and S. Klimašauskas, “5-Hydroxymethylcytosine: The Many Faces of the Sixth Base of Mammalian DNA,” Chem. Soc. Rev. (2024), https://doi.org/10.1039/d3cs00858d.

[393] M. Bachman, S. Uribe-Lewis, X. Yang, M. Williams, A. Murrell, and S. Balasubramanian, “5-Hydroxymethylcytosine Is a Predominantly Stable DNA Modification,” Nature Chemistry 6 (2014): 1049-1055.

[394] A. K. Singh, R. Kumar, and A. K. Pandey, “Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers,” Current Chemical Genomics and Translational Medicine 12 (2018): 9-26.

[395] K. Chen, J. Zhang, Z. Guo, et al., “Loss of 5-hydroxymethylcytosine Is Linked to Gene Body Hypermethylation in Kidney Cancer,” Cell Research 26 (2016): 103-118.

[396] C. Zeng, E. K. Stroup, Z. Zhang, B. C. Chiu, and W. Zhang, “Towards Precision Medicine: Advances in 5-hydroxymethylcytosine Cancer Biomarker Discovery in Liquid Biopsy,” Cancer Commun (Lond) 39 (2019): 12.

[397] C. Song, S. Yin, L. Ma, et al., “5-Hydroxymethylcytosine Signatures in Cell-free DNA Provide Information About Tumor Types and Stages,” Cell Research 27 (2017): 1231-1242.

[398] T. Xu and H. Gao, “Hydroxymethylation and Tumors: Can 5-hydroxymethylation be Used as a Marker for Tumor Diagnosis and Treatment?,” Human Genomics 14 (2020): 15.

[399] W. Li, X. Zhang, X. Lu, et al., “5-Hydroxymethylcytosine Signatures in Circulating Cell-free DNA as Diagnostic Biomarkers for human Cancers,” Cell Research 27 (2017): 1243-1257.

[400] S. N. Kamdar, L. T. Ho, K. J. Kron, et al., “Dynamic Interplay Between Locus-specific DNA Methylation and Hydroxymethylation Regulates Distinct Biological Pathways in Prostate Carcinogenesis,” Clinical Epigenetics 8 (2016): 32.

[401] X. Tian, B. Sun, C. Chen, et al., “Circulating Tumor DNA 5-hydroxymethylcytosine as a Novel Diagnostic Biomarker for Esophageal Cancer,” Cell Research 28 (2018): 597-600.

[402] N. Gilat, T. Tabachnik, A. Shwartz, et al., “Single-molecule Quantification of 5-hydroxymethylcytosine for Diagnosis of Blood and Colon Cancers,” Clinical Epigenetics 9 (2017): 70.

[403] J. Zhang, X. Han, C. Gao, et al., “5-Hydroxymethylome in Circulating Cell-free DNA as a Potential Biomarker for Non-small-cell Lung Cancer,” Genomics, Proteomics & Bioinformatics 16 (2018): 187-199.

[404] M. Sjöström, S. G. Zhao, S. Levy, et al., “The 5-Hydroxymethylcytosine Landscape of Prostate Cancer,” Cancer Research 82 (2022): 3888-3902.

[405] B. C. Chiu, Q. You, Z. Zhang, et al., “5-Hydroxymethylcytosine of Circulating Cell-Free DNA in Plasma: A Novel Non-Invasive Marker for Progression and Prognosis in Multiple Myeloma,” Blood 130 (2017): 4336-4336.

[406] J. Cai, L. Chen, Z. Zhang, et al., “Genome-wide Mapping of 5-hydroxymethylcytosines in Circulating Cell-free DNA as a Non-invasive Approach for Early Detection of Hepatocellular Carcinoma,” Gut 68 (2019): 2195-2205.

[407] W. Liu, M. Tian, L. Jin, et al., “High Expression of 5-hydroxymethylcytosine and Isocitrate Dehydrogenase 2 Is Associated With Favorable Prognosis After Curative Resection of Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 33 (2014): 32.

[408] G. D. Guler, Y. Ning, C. Ku, et al., “Detection of Early Stage Pancreatic Cancer Using 5-hydroxymethylcytosine Signatures in Circulating Cell Free DNA,” Nature Communications 11 (2020): 5270.

[409] J. Shao, S. Shah, S. Ganguly, Y. Zu, C. He, and Z. Li, “Cell-free DNA 5-hydroxymethylcytosine Is Highly Sensitive for MRD Assessment in Acute Myeloid Leukemia,” Clinical Epigenetics 15 (2023): 134.

[410] G. Liang, L. Wang, Q. You, et al., “Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined With Chemotherapy,” Advanced Science (Weinheim) 10 (2023): e2300445.

[411] B. Szabó, K. Németh, K. Mészáros, et al., “Demethylation Status of Somatic DNA Extracted from Pituitary Neuroendocrine Tumors Indicates Proliferative Behavior,” Journal of Clinical Endocrinology and Metabolism 105 (2020), https://doi.org/10.1210/clinem/dgaa156.

[412] S. Gomez, T. Tabernacki, J. Kobyra, P. Roberts, and K. B. Chiappinelli, “Combining Epigenetic and Immune Therapy to Overcome Cancer Resistance,” Seminars in Cancer Biology 65 (2020): 99-113.

[413] L. Gillberg, A. D. Ørskov, et al., “Oral Vitamin C Supplementation to Patients With Myeloid Cancer on Azacitidine Treatment: Normalization of Plasma Vitamin C Induces Epigenetic Changes,” Clinical Epigenetics 11 (2019): 143.

[414] H. Zhao, H. Zhu, J. Huang, et al., “The Synergy of Vitamin C With Decitabine Activates TET2 in Leukemic Cells and Significantly Improves Overall Survival in Elderly Patients With Acute Myeloid Leukemia,” Leukemia Research 66 (2018): 1-7.

[415] J. P. Brabson, T. Leesang, Y. S. Yap, et al., “Oxidized mC Modulates Synthetic Lethality to PARP Inhibitors for the Treatment of Leukemia,” Cell reports 42 (2023): 112027.

[416] D. Peng, A. He, S. He, et al., “Ascorbic Acid Induced TET2 Enzyme Activation Enhances Cancer Immunotherapy Efficacy in Renal Cell Carcinoma,” International Journal of Biological Sciences 18 (2022): 995-1007.

[417] T. C. Huff, D. W. Sant, V. Camarena, et al., “Vitamin C Regulates Schwann Cell Myelination by Promoting DNA Demethylation of Pro-myelinating Genes,” Journal of Neurochemistry 157 (2021): 1759-1773.

[418] K. C. Morris-Blanco, A. K. Chokkalla, T. Kim, et al., “High-Dose Vitamin C Prevents Secondary Brain Damage after Stroke via Epigenetic Reprogramming of Neuroprotective Genes,” Translational Stroke Research 13 (2022): 1017-1036.

[419] N. Shenoy, T. D. Bhagat, J. Cheville, et al., “Ascorbic Acid-induced TET Activation Mitigates Adverse Hydroxymethylcytosine Loss in Renal Cell Carcinoma,” Journal of Clinical Investigation 129 (2019): 1612-1625.

[420] D. Peng, G. Ge, Y. Gong, et al., “Vitamin C Increases 5-hydroxymethylcytosine Level and Inhibits the Growth of Bladder Cancer,” Clinical Epigenetics 10 (2018): 94.

[421] Y. Guan, E. F. Greenberg, M. Hasipek, et al., “Context Dependent Effects of Ascorbic Acid Treatment in TET2 Mutant Myeloid Neoplasia,” Communications Biology 3 (2020): 493.

[422] R. A. Luchtel, T. Bhagat, K. Pradhan, et al., “High-dose Ascorbic Acid Synergizes With Anti-PD1 in a Lymphoma Mouse Model,” Pnas 117 (2020): 1666-1677.

[423] G. Ge, D. Peng, Z. Xu, et al., “Restoration of 5-hydroxymethylcytosine by Ascorbate Blocks Kidney Tumour Growth,” Embo Reports 19 (2018), https://doi.org/10.15252/embr.201745401.

[424] L. Cimmino, I. Dolgalev, Y. Wang, et al., “Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression,” Cell 170 (2017): 1079-1095.e1020.

[425] M. Agathocleous, C. E. Meacham, R. J. Burgess, et al., “Ascorbate Regulates Haematopoietic Stem Cell Function and Leukaemogenesis,” Nature 549 (2017): 476-481.

[426] H. Kim, I. Jung, C. H. Lee, J. An, and M. Ko, “Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins,” International Journal of Molecular Sciences 24 (2023), https://doi.org/10.3390/ijms242216375.

[427] H. Zhao, J. Lu, T. Yan, et al., “Opioid Receptor Signaling Suppresses Leukemia Through both Catalytic and Non-catalytic Functions of TET2,” Cell reports 38 (2022): 110253.

[428] S. Atlante, A. Visintin, E. Marini, et al., “α-ketoglutarate Dehydrogenase Inhibition Counteracts Breast Cancer-associated Lung Metastasis,” Cell death & disease 9 (2018): 756.

[429] I. K. Mellinghoff, M. Lu, P. Y. Wen, et al., “Vorasidenib and ivosidenib in IDH1-mutant Low-grade Glioma: A Randomized, Perioperative Phase 1 Trial,” Nature Medicine 29 (2023): 615-622.

[430] K. Yen, J. Travins, F. Wang, et al., “AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations,” Cancer discovery 7 (2017): 478-493.

[431] L. Chen, A. Ren, Y. Zhao, et al., “Direct Inhibition of Dioxygenases TET1 by the Rheumatoid Arthritis Drug auranofin Selectively Induces Cancer Cell Death in T-ALL,” Journal of hematology & oncology 16 (2023): 113.

[432] H. Lv, J. Catarino, D. Li, et al., “A Small-molecule Degrader of TET3 as Treatment for Anorexia Nervosa in an Animal Model,” Pnas 120 (2023): e2300015120.

[433] L. Chen, C. Morcelle, Z. Cheng, et al., “Itaconate Inhibits TET DNA Dioxygenases to Dampen Inflammatory Responses,” Nature Cell Biology 24 (2022): 353-363.

[434] X. Jiang, C. Hu, K. Ferchen, et al., “Targeted Inhibition of STAT/TET1 Axis as a Therapeutic Strategy for Acute Myeloid Leukemia,” Nature Communications 8 (2017): 2099.

[435] H. Kim, Y. Kang, Y. Li, et al., “Ten-eleven Translocation Protein 1 Modulates Medulloblastoma Progression,” Genome biology 22 (2021): 125.

[436] X. Hu, C. Dasgupta, M. Chen, et al., “Pregnancy Reprograms Large-Conductance Ca(2+)-Activated K(+) Channel in Uterine Arteries: Roles of Ten-Eleven Translocation Methylcytosine Dioxygenase 1-Mediated Active Demethylation,” Hypertension 69 (2017): 1181-1191.

[437] Y. Guan, M. Hasipek, D. Jiang, et al., “Eltrombopag Inhibits TET Dioxygenase to Contribute to Hematopoietic Stem Cell Expansion in Aplastic Anemia,” Journal of Clinical Investigation 132 (2022), https://doi.org/10.1172/jci149856.

[438] A. K. Singh, B. Zhao, X. Liu, et al., “Selective Targeting of TET Catalytic Domain Promotes Somatic Cell Reprogramming,” Pnas 117 (2020): 3621-3626.

[439] Y. Guan, A. D. Tiwari, J. G. Phillips, et al., “A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms,” Blood Cancer Discovery 2 (2021): 146-161.

[440] T. Kietzmann, “From Nutrition to Oxygen Sensing and Epigenetics,” Redox Biology 63 (2023): 102753.

[441] B. Ngo, J. M. Van Riper, L. C. Cantley, and J. Yun, “Targeting Cancer Vulnerabilities With High-dose Vitamin C,” Nature Reviews Cancer 19 (2019): 271-282.

[442] K. Bian, S. A. P. Lenz, Q. Tang, et al., “DNA Repair Enzymes ALKBH2, ALKBH3, and AlkB Oxidize 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine in Vitro,” Nucleic Acids Res. 47 (2019): 5522-5529.

[443] Y. Huang and A. Rao, “Connections Between TET Proteins and Aberrant DNA Modification in Cancer,” Trends in Genetics 30 (2014): 464-474.

[444] M. Liu, H. Ohtani, W. Zhou, et al., “Vitamin C Increases Viral Mimicry Induced by 5-aza-2'-deoxycytidine,” Pnas 113 (2016): 10238-10244.

[445] M. J. Huijskens, W. K. Wodzig, M. Walczak, W. T. Germeraad, and G. M. Bos, “Ascorbic Acid Serum Levels Are Reduced in Patients With Hematological Malignancies,” Results in Immunology 6 (2016): 8-10.

[446] P. L. Mouchel, E. Bérard, S. Tavitian, et al., “Vitamin C and D Supplementation in Acute Myeloid Leukemia,” Blood Advances 7 (2023): 6886-6897.

[447] X. Yue and A. Rao, “TET family Dioxygenases and the TET Activator Vitamin C in Immune Responses and Cancer,” Blood 136 (2020): 1394-1401.

[448] S. U. Mikkelsen, L. Gillberg, J. Lykkesfeldt, and K. Grønbæk, “The Role of Vitamin C in Epigenetic Cancer Therapy,” Free Radical Biology & Medicine 170 (2021): 179-193.

[449] B. A. Woods and R. L. Levine, “The Role of Mutations in Epigenetic Regulators in Myeloid Malignancies,” Immunological Reviews 263 (2015): 22-35.

[450] A. C. Carr and J. Cook, “Intravenous Vitamin C for Cancer Therapy—Identifying the Current Gaps in Our Knowledge,” Frontiers in Physiology 9 (2018): 1182.

[451] B. J. Evison, B. E. Sleebs, K. G. Watson, D. R. Phillips, and S. M. Cutts, “Mitoxantrone, More Than Just another Topoisomerase II Poison,” Medicinal Research Reviews 36 (2016): 248-299.

[452] E. Cocco and M. G. Marrosu, “The Current Role of Mitoxantrone in the Treatment of Multiple Sclerosis,” Expert review of neurotherapeutics 14 (2014): 607-616.

[453] M. Enache, A. M. Toader, and M. I. Enache, “Mitoxantrone-Surfactant Interactions: A Physicochemical Overview,” Molecules (Basel, Switzerland) 21 (2016), https://doi.org/10.3390/molecules21101356.

[454] W. Tian, W. Zhang, Y. Wang, et al., “Recent Advances of IDH1 Mutant Inhibitor in Cancer Therapy,” Frontiers in pharmacology 13 (2022): 982424.

[455] Enasidenib Approved for AML, but Best Uses Unclear. Cancer discovery 7, Of4, (2017).

[456] E. M. Stein, C. D. DiNardo, A. T. Fathi, et al., “Ivosidenib or enasidenib Combined With Intensive Chemotherapy in Patients With Newly Diagnosed AML: A Phase 1 Study,” Blood 137 (2021): 1792-1803.

[457] G. K. Abou-Alfa, T. Macarulla, M. M. Javle, et al., “Ivosidenib in IDH1-mutant, Chemotherapy-refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study,” The Lancet Oncology 21 (2020): 796-807.

[458] T. Gamberi, G. Chiappetta, T. Fiaschi, A. Modesti, F. Sorbi, and F. Magherini, “Upgrade of an Old Drug: Auranofin in Innovative Cancer Therapies to Overcome Drug Resistance and to Increase Drug Effectiveness,” Medicinal Research Reviews 42 (2022): 1111-1146.

[459] M. Yamashita, “Auranofin: Past to Present, and Repurposing,” International Immunopharmacology 101 (2021): 108272.

[460] H. Sun, Q. Zhang, R. Wang, et al., “Resensitizing Carbapenem- and Colistin-resistant Bacteria to Antibiotics Using auranofin,” Nature Communications 11 (2020): 5263.

[461] G. N. L. Chua, K. L. Wassarman, H. Sun, et al., “Cytosine-Based TET Enzyme Inhibitors,” Acs Medicinal Chemistry Letters 10 (2019): 180-185.

[462] Q. Shi, R. Liu, and L. Chen, “Ferroptosis Inhibitor ferrostatin-1 Alleviates- -Homocysteineinduced- Ovarian- Granulosa- Cell- Injury- by Regulating- TET Activity- and DNA Methylation-,” Molecular Medicine Reports 25 (2022), https://doi.org/10.3892/mmr.2022.12645.

[463] C. Dusadeemeelap, T. Rojasawasthien, T. Matsubara, S. Kokabu, and W. N. Addison, “Inhibition of TET-mediated DNA Demethylation Suppresses Osteoblast Differentiation,” Faseb Journal 36 (2022): e22153.

[464] M. C. Runtsch and L. A. O'Neill, “Pseudomonas Persists by Feeding off Itaconate,” Cell metabolism 31 (2020): 1045-1047.

[465] H. H. Luan and R. Medzhitov, “Food Fight: Role of Itaconate and Other Metabolites in Antimicrobial Defense,” Cell metabolism 24 (2016): 379-387.

[466] H. Huang, X. Jiang, J. Wang, et al., “Identification of MLL-fusion/MYC⊣miR-26⊣TET1 Signaling Circuit in MLL-rearranged Leukemia,” Cancer Letters 372 (2016): 157-165.

[467] H. Huang, X. Jiang, Z. Li, et al., “TET1 plays an Essential Oncogenic Role in MLL-rearranged Leukemia,” Pnas 110 (2013): 11994-11999.

[468] J. Astorga, N. Gasaly, K. Dubois-Camacho, et al., “The Role of Cholesterol and Mitochondrial Bioenergetics in Activation of the Inflammasome in IBD,” Frontiers in immunology 13 (2022): 1028953.

[469] M. Xiao, H. Yang, W. Xu, et al., “Inhibition of α-KG-dependent Histone and DNA Demethylases by Fumarate and Succinate That Are Accumulated in Mutations of FH and SDH Tumor Suppressors,” Genes & development 26 (2012): 1326-1338.

[470] T. Laukka, C. J. Mariani, T. Ihantola, et al., “Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes,” Journal of Biological Chemistry 291 (2016): 4256-4265.

[471] Y. Tong, Y. Qi, G. Xiong, et al., “The PLOD2/Succinate Axis Regulates the Epithelial-mesenchymal Plasticity and Cancer Cell Stemness,” Pnas 120 (2023): e2214942120.

[472] K. Uh, J. Ryu, K. Farrell, N. Wax, and K. Lee, “TET family Regulates the Embryonic Pluripotency of Porcine Preimplantation Embryos by Maintaining the DNA Methylation Level of NANOG,” Epigenetics 15 (2020): 1228-1242.

[473] D. Zhang, X. An, Z. Li, and S. Zhang, “Role of Gene Promoter Methylation Regulated by TETs and DNMTs in the Overexpression of HLA-G in MCF-7 Cells,” Experimental And Therapeutic Medicine 17 (2019): 4709-4714.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.